Form PTO-1390 (RaiV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

ATTORNEY'S DOCKET NUMBER
9013.43
U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

				3 UNDER 35 U	J.S.C. 371	10/069082								
PC	CT/GE	NATIONAL APPI 300/03159	LICATION NO.	INTERNATIONAL 16 August 2000	FILING DATE	PRIORITY DATE CLAIMED 18 August 1999								
		E OF INVENTION												
		JICANT(S) FOR DO/EO/US												
		el GALBRAITH; Helena KELLY; Kenneth SMITH												
A	Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information													
1.		This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.												
2.	ᆜ	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.												
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.												
4.1	_													
5.		(Attack 31).												
1	ы	a. is attached hereto (required only if not communicated by the International Bureau).												
		b. has been communicated by the International Bureau.												
		c. is not required, as the application was filed in the United States Receiving Office (RO/US).												
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).												
		_	ached hereto.			0.071(0)(2)).								
		b. has b	een previously subm	itted under 35 U.S.C.	154(d)(4)									
7.		Amendments to	the claims of the Inte	ernational Application	Under PCT Article 19	(35 U.S.C. 371(c)(3))								
		a. are at	ttached hereto (requir	red only if not commu	inicated by the Internat	ional Bureau).								
		b. 🗌 have	been communicated	by the International E	Bureau.									
		c. have	not been made; howe	ever, the time limit fo	r making such amendm	ents has NOT expired.								
	_		not been made and w											
8.						cle 19 (35 U.S.C. 371(c)(3)).								
9.				r(s) (35 U.S.C. 371(c)										
10.	Ш			e annexes of the Inter	national Preliminary E	xamination Report Under PCT								
		Article 36 (35 U	.S.C. 371(c)(5)).											
	Iton	no 11 to 20 balan		(-)t. f										
11				(s) or information in under 37 CFR 1.97 a										
						h 37 CFR 3.28 and 3.31 is included.								
	_			ig. A separate cover :	sneet in compitance wit	n 37 CFR 3.28 and 3.31 is included.								
14.		A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.												
15.		A substitute specification.												
		-	er of attorney and/or	address letter.										
					lance with PCT Rule 13	Bter.2 and 35 U.S.C. 1.821 - 1.825.								
					nder 35 U.S.C. 154(d)(4									
19.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4)												
				Opinion; International										

U.S.	APPL	ICATTINOD, JEKO	6.9082 PC	ERNATIONAL APPLICATION F/GB00/03159	N NO.	ATTORNEY DOCKET NO 9013.43						
		The following fees a NATIONAL FEE				CALCULATIONS	PTO USE ONLY					
пог	inter	national search fce	inary examination fee (3 (37 CFR 1.445(a)(2)) pa port not prepared by the	id to USPTO	\$1040.00							
	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO											
	International preliminary examination fee 37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO											
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)												
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)												
			ENTER A	PPROPRIATE BASE I	EE AMOUNT =							
			iority date (37 CFR 1.49		30 months	s	*					
CL	AIM	S	NUMBER FILED	NUMBER EXTRA	RATE	\$						
Tot	al cl	aims	19 - 20 =	0	x \$18.00	\$						
		dent Claims	1 - 3 =	0	x \$84.00	\$						
MU	JLTI	PLE DEPENDEN	VT CLAIM(S) (if appl	icable)	+ \$280.00	\$280.00						
			TOTAL	OF ABOVE CALC	ULATIONS =	\$1320.00						
		licant claims small seed by 1/2	entity status. See 37 CF	R 1.27. The fees indicate	ed above are	\$						
				S	UBTOTAL =	\$1320.00						
			or furnishing the English imed priority date (37 C)	translation later than 🔲 🗆		\$						
}				TOTAL NATI	ONAL FEE =	\$1320.00						
Fee	for R	ecording the enclos	sed assignment (37 CFR iate cover sheet (37 CFR	1.21(h)). The assignmen 3.28, 3.31). \$40.00 per p	t must be	s						
				TOTAL FEES E		\$1320.00						
						Amount to be refunded:	s					
						charged:	\$					
a,	Ø	A check in the ame	ount of \$1320.00 to cove	r the above fees is enclos	ed.							
b.												
c.	_											
		The Commissioner	r is hereby authorized to	charge any additional fee	s which may be req							
d.		The Commissioner to Deposit Accoun	r is hereby authorized to at No. 50-0220. A duplic ged to a credit card. W	charge any additional fee ate copy of this sheet is e	s which may be req nclosed. n this form may be	uired, or credit any over	payment					
·NO:	TE:	The Commissioner to Deposit Account Fees are to be char information shoult Where an appropriate to the commission of the	r is hereby authorized to at No. 50-0220. A duplic rged to a credit card. Wa ld not be included on the riate time limit under 3	charge any additional fee ate copy of this sheet is e ARNING: Information o tis form. Provide credit of 7 CFR 1.494 or 1.495 ha	s which may be req nclosed. n this form may be ard information an	uired, or credit any over come public. Credit car d authorization on PTO-	payment rd 2038.					
·NO:	TE:	The Commissioner to Deposit Account Fees are to be char information shoult Where an appropriate to the commission of the	r is hereby authorized to tt No. 50-0220. A duplic ged to a credit card. Wa ld not be included on th	charge any additional fee ate copy of this sheet is e ARNING: Information o tis form. Provide credit of 7 CFR 1.494 or 1.495 ha	s which may be req nclosed. n this form may be ard information an	uired, or credit any over come public. Credit car d authorization on PTO-	payment rd 2038.					
NO:	TE:	The Commissioner to Deposit Account Fees are to be char information shoult Where an appropriate to the commission of the	r is hereby authorized to at No. 50-0220. A duplic rged to a credit card. W, ld not be included on the riate time limit under 3 to restore the application	charge any additional fee ate copy of this sheet is e ARNING: Information o his form. Provide credit of 7 CFR 1.494 or 1.495 ha n to pending status.	s which may be req nclosed. n this form may be ard information an	uired, or credit any over come public. Credit can d authorization on PTO- petition to relian (37 C)	payment rd 2038.					
NO:	TE:	The Commissioner to Deposit Account Fees are to be char information should Where an appropriiled and granted to LL CORRESPOND	r is hereby authorized to tt No. 50-0220. A duplic gged to a credit card. W. Id not be included on the riate time limit under 3 to restore the application DENCE TO:	charge any additional fee ate copy of this sheet is e ARNING: Information o its form. Provide credit of 7 CFR 1.494 or 1.495 ha n to pending status.	s which may be requeled. In this form may be and information and so not been freet, a process of the source of th	uired, or credit any over come public. Credit ca d authorization on PTO- netition to 18% (37 C)	payment rd 2038.					
NO:	TE:	The Commissioner to Deposit Account Fees are to be char information should Where an appropriited and granted to	r is hereby authorized to tt No. 50-0220. A duplic gged to a credit card. W. Id not be included on the riate time limit under 3 to restore the application DENCE TO:	charge any additional fee ate copy of this sheet is e ARNING: Information o its form. Provide credit of 7 CFR 1.494 or 1.495 ha n to pending status.	s which may be req nelosed. In this form may bee ard information and s not been finet, a p	uired, or credit any over come public. Credit can d authorization on PTO- netition to refuy (37 C) Reg. #31,665	payment rd 2038. FR 1.137(a) or (h))					
NO:	TE:	The Commissioner to Deposit Account Fees are to be char information shoul Where an appropriited and granted to LL CORRESPOND	r is hereby authorized to it No. 50-0220. A duplic rged to a credit card. W. Id not be included on the riate time limit under 3 to restore the application DENCE TO:	charge any additional fee atc copy of this sheet is e ARNING: Information o its form. Provide credit of 7 CFR 1.494 or 1.495 ha n to pending status.	s which may be req nclosed. In this form may be ard information an s not been net, a [uired, or credit any over come public. Credit ear d authorization on PTO- nectition to cyflyd (37 C: Reg. #31,665)	payment rd 2038. FR 1.137(a) or (h))					
NO:	TE:	The Commissioner to Deposit Account Fees are to be char information shoul Where an appropriiled and granted to LL CORRESPOND	r is hereby authorized to tt No. 50-0220. A duplic rged to a credit card. W/ Id not be included on the riate time limit under 3 to restore the application DENCE TO:	charge any additional fee ate copy of this sheet is e ARNING: Information o its form. Provide credit or 7 CFR 1.494 or 1.495 ha n to pending status.	s which may be req nclosed. In this form may be ard information an s not been finet, a [a Kenneth D. Sibley, Date: <u>February</u> il Label No. EVOISS il Lose Vois February 15, 20	uired, or credit any over come public. Credit cat a uthorization on PTO- betition to gray (37 C. Reg. #31,665 15, 200	payment rd 2038. FR 1.137(a) or (b))					
NO:	TE:	The Commissioner to Deposit Account Fees are to be char information shoul Where an appropriited and granted to LL CORRESPOND	r is hereby authorized to tt No. 50-0220. A duplic rged to a credit card. W/ Id not be included on the riate time limit under 3 to restore the application DENCE TO:	charge any additional fee afe copy of this sheet is e RRNING: Information o is form. Provide credit o 7 CFR 1.494 or 1.495 ha n to pending status. Express Ma Date of Dep Here States Posts 1.10 on the	s which may be req nclosed. In this form may be ard information an s not been/net, a [a Kenneth D. Sibley, Date:February ii Label No. FVOIS& iii Label No. FVOIS& jox Certify that this con I Service "Expris that this con	uired, or credit any over come public. Credit car d authorization on PTO- netition to 1851 (37 Ct Reg. #31,665 15, 2000 VTE OF EXPRESS MAII 3090021US 2010 (30 december 2) (40 Addresses unit book of the OAddresse	payment rd 2038. FR 1.137(a) or (b)) LING sited with the United c' service under 37 CFR					



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re-U.S. Serial No : Galbraith, et al. 10/069.082

Int'l Filing Date:

Int'l Application No.: PCT/GB00/03159 August 26, 2000

RETROVIRUS ASSAY

October 25, 2002

Commissioner for Patents Washington, DC 20231

STATEMENT IN SUPPORT OF FILING A SEOUENCE LISTING UNDER 37 CFR § 1.821(f)

Sir:

For:

Submitted herewith is a copy of the Sequence Listing in computer readable form. I hereby state that the content of the paper and computer readable copies of the Sequence listing are the same. I also hereby state as required by 37 CFR § 1.821(h) that the computer readable copy submitted concurrently herewith contains no new matter, nor does it go beyond the disclosure of the application as filed.

Respectfully submitted

Michael Saiovec Registration No. 31,793

20792

PATENT TRADEMARK OFFICE

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on October 25, 2002.

Vickie Diane Prior

Date of Signature: October 25, 2002

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

In re: Serial No Galbraith, et al. To Be Assigned

Filed:

Concurrently Herewith

For:

RETROVIRUS ASSAY

February 15, 2002

Box PCT Attn: DO/US Commissioner for Patents Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above application, please amend the above-identified application as follows. If any extension of time for the accompanying response or submission is required, Applicant requests that this be considered a petition therefor. The Commissioner is hereby authorized to charge any additional fee, which may be required, or credit any refund, to our Deposit Account No. 50-0220.

In the Specification:

-- RELATED APPLICATIONS

The present application claims priority from International Application No. PCT/GB00/03159, filed on 16 August 2000, which in turn claims priority from British application 9919604.0, filed on 18 August 1999, the disclosures of which are hereby incorporated herein by reference in their entirety.--

In the Claims:

Please enter the following amended claims:

13 (amended). An antiserum specific to a polypeptide fragment in accordance with Claim 1. In re: Galbraith, et al. International Appl. No. PCT/GB00/03159 International Filing Date: 16 August 2000 Page 2

14 (amended). A PoERV specific antibody or fragment thereof raised against a polypeptide fragment in accordance with Claim 1.

16 (amended). Use of a polypeptide fragment according to Claim 1 in detection of PoERV antibodies in a sample.

18 (amended). An assay kit for use in detection of PoERV antibodies in a sample, the kit comprising a polypeptide fragment in according with Claim 1.

19 (amended). Use of an antibody according to Claim 14, or a polypeptide fragment according to Claim 1 in therapy or diagnosis.

In re: Galbraith, et al. International Appl. No. PCT/GB00/03159 International Filing Date: 16 August 2000 Page 3

REMARKS

Claims 1-19 are presented for examination. The above claims have been amended to better conform to U.S. practice. Applicants respectfully request substantive examination on the merits. A copy of the claims showing the changes made is attached hereto as a "Version with Markings to Show Changes Made".

Respectfully submitted.

Kenneth D. Sibley

Registration No. 31

20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label number EL015808902US Date of Deposit: February 15, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Commissioner for Patents, Washington, DC 20231.

Vickie Diane Prior

Date of Signature: February 15, 2002

In re: Galbraith, et al.

International Appl. No. PCT/GB00/03159 International Filing Date: 16 August 2000

Page 4

VERSION WITH MARKINGS TO SHOW CHANGES MADE

13 (amended). An antiserum specific to a polypeptide fragment in accordance with [any preceding claim] Claim 1.

14 (amended). A PoERV specific antibody or fragment thereof raised against a polypeptide fragment in accordance with [any of] Claim[s] 1 [to 12].

16 (amended). Use of a polypeptide fragment according to [any one of] Claim[s] 1 [to 12] in detection of PoERV antibodies in a sample.

18 (amended). An assay kit for use in detection of PoERV antibodies in a sample, the kit comprising a polypeptide fragment in according with [any of] Claim[s] 1 [to 12].

19 (amended). Use of an antibody according to Claim 14, or a polypeptide fragment according to [any one of] Claim[s] 1 [to 12] in therapy or diagnosis.

5

10

15

20

25

PCT/GB00/03159

1 RETROVIRUS ASSAY

The present invention relates inter alia to porcine endogenous retrovirus (PoERV) fragments, in particular to gag and env fragments of PoERV. The invention relates further to use of such fragments in detection of PoERV or detection of exposure to PoERV. There is also provided antibodies to gag and env polynucleotides and polypeptides; kits for the detection of PoERV or exposure to PoERV; and env peptides and antisera specific for the various types of PoERV and use of such peptides and antisera in the detection of specific PoERV types.

Porcine endogenous retrovirus (PoERV) is an endogenous Gammaretrovirus present typically as a provirus found in several loci in the porcine genome. The proviral genome can be silent or is expressed. Expression of the virus was found to be associated with leukaemic pigs (Strandstrom et al, 1974) and some continuous porcine cell lines produce POERV (Todaro et al, 1974). Virus from these cells has been shown to infect non-porcine cell-types including human cells (Galbraith et al, 1997; Patience et al, 1997). Three subgroups of PoERV have been described and are designated POERV A, B and C dependent on the tropism of the virus and the related envelope gene structure (Onions et al, 1998). Only subtypes A and B have been shown to be capable of consistently infecting human cells in vitro. Subgroup C PoERV from mini-pigs has only been shown to infect one human cell line and this may reflect a low capacity for

10

15

20

25

2

infection of human cells. Since PoERV is expressed in pigs there is the potential for virus to be present in material prepared from pigs. Furthermore, as a consequence of xenotransplantation using porcine donor organs, there is the possibility that the endogenous virus will be expressed in vivo and be a potential risk of PoERV infection of the patient and the general population thereafter.

A number of different types of PoERV are known, based on their genetic makeup. Types designated PERV A, PERV B, and PoEV1 are described in International Patent Application W097/40167, while types designated PERV MSL and Tsukuba are described in International Patent Application W097/21836.

PoERV viruses comprise three genes: gag, pol, and env, generating GAG, POL and ENV polypeptides. It has been observed that the gag region of the genome appears to be substantially conserved among different viruses, as well as between PoERV virus types, while the env region contains both conserved and non-conserved regions, which non-conserved regions are observed to vary between viral types.

It is among the objects of the present invention to provide means whereby patients and/or samples may be monitored for viral infection. It is further among the objects of the present invention to provide means whereby the viral type may be determined.

According to one aspect of the present invention there is provided a PoERV polypeptide fragment, wherein said polypeptide fragment has PoERV specific antigenic or immunogenic activity. Antigenic or immunogenic activity is

10

15

20

25

PCT/GB00/03159

3

to be understood as capable of eliciting a PoERV specific immune response when introduced into a normal mammalian host. For example, PoERV specific antibodies are produced as a consequence.

According to a further aspect of the present invention there is provided an antiserum specific to a POERV polypeptide fragment as described above.

According to one aspect of the present invention, there is provided a fragment of a PoERV GAG polypeptide, wherein said fragment has PoERV specific antigenic or immunogenic activity. Such a fragment will be referred to hereinafter as a GAG peptide, it being understood that this is distinct from native GAG protein, and may comprise only a fragment thereof, provided the GAG peptide has antigenic activity. The consensus PoERV GAG polypeptide sequence is shown in Figure 1; in preferred embodiments of the invention, the GAG peptide may be selected from within this sequence.

According to a further aspect of the present invention, there is provided a fragment of a PoERV ENV polypeptide, wherein said fragment has PoERV specific antigenic or immunogenic activity. Such a fragment will be referred to hereinafter as an ENV peptide, it being understood that this is distinct from native ENV protein, and may comprise only a fragment thereof, provided the ENV peptide has antigenic activity. In one embodiment, the ENV peptide may be selected from within a conserved region of the various PoERV sequences, as illustrated in Figures 2

WO 01/12816 PCT/GB00/03159

Conserved regions are those which comprise and 3. identical and/or highly conserved amino acid sequences in different PoERV virus types; wholly conserved amino acids are indicated in Figures 2 and 3 by an asterisk beneath the amino acid, with highly conserved amino acids being indicated by a colon. Alternatively, the ENV peptide may be selected from within the non-conserved regions of the various PoERV sequences of Figures 2 and 3, in which case the ENV peptide will be specific for a particular type of PoERV. Specific examples of non-conserved type-specific ENV peptides are shown as peptides D-H and J in Figure 3 In a third embodiment, the ENV peptide may comprise both a conserved and a non-conserved region of the POERV ENV protein, from either adjacent or non-adjacent regions of the ENV protein. Such peptides may be considered useful in simultaneous detection of any PoERV virus and a specific viral type.

10

15

20

25

In a further aspect of the present invention, there is provided a fusion GAG/ENV peptide, which peptide comprises both GAG peptide sequences and ENV peptide sequences. Such peptide may be considered useful in simultaneous detection of any PoERV virus, by means of the GAG peptide, and a specific viral type, by means of the ENV peptide.

According to a yet further aspect of the present invention there is provided antibodies specific to either GAG or ENV peptides. The antibodies may be polyclonal or monoclonal. Such antibodies can include, but are not limited to, polyclonal antibodies, monoclonal antibodies

15

20

25

5

(mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab'), fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. The Ig tails of such antibodies can be modified to reduce complement activation and Fc binding, (See, for example, European Patent No. 239400 Bl, Aug. 3, 1994).

For the production of antibodies to a peptide, various host animals can be immunized by injection with a peptide, or a portion thereof. Such host animals can include but are not limited to rabbits, mice, and rats, to name but a few. Various adjuvants can be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Gurein) and Corynebacterium parvum.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as target gene product, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, can be immunized by injection with a gene product supplemented with adjuvants as also described above.

10

15

20

25

Monoclonal antibodies. which are homogeneous populations of antibodies to a particular antigen, can be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to the hybridoma technique of Kohler and Milsrein. (1975. Nature 256:495-497; and US Pat. No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030). and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Anti-bodies And Cancer Therapy, Alan R. Liss, Inc., pp.77-96).

Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention can be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.

In addition, techniques for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452-454; U.S. Pat. No. 4,816,567) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable

10

15

20

25

region derived from a murine mAb and a human immunoglobulin constant region.

Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778: Bird, 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:5879-5883; and Ward et al., 1989, Nature 334:544-546) and for making humanized monoclonal antibodies (U.S. Pat. No. 5,225,539) can be utilized to produce anti-differentially expressed or anti-pathway gene product antibodies.

Antibody fragments which recognize specific epitopes can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries can be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Further aspects of the present invention provide methods of screening serum or tissue from humans or animal recipients of porcine tissue for exposure to PoERV. These methods include: use of antibodies to GAG or ENV peptides in the capture and/or detection of PoERV antigens; use of antibodies to GAG or ENV peptides in the detection of PoERV gene expression in virus infected cells by indirect immunofluorescence staining; the use of antibodies to GAG

WO 01/12816 PCT/GB00/03159

8

or ENV peptides in the visualisation of PoERV virions in a sample by immuno-electron microscopy; use of GAG or ENV peptides in Western blotting for the detection of PoERV antibodies in samples from recipients of porcine-derived materials; and the use of GAG or ENV peptides in an enzymelinked immunosorbent assay (ELISA) for the detection of PoERV antibodies.

Each of these methods may non-specifically detect any PoERV type (if GAG peptides, conserved ENV peptides or antibodies are used) or specific PoERV types, if type-specific non-conserved ENV peptides or antibodies are used.

10

15

20

25

The present invention also encompasses assay kits including GAG or ENV peptides or antibodies to such peptides, for use in the abovementioned assays. In preferred embodiments, the kits may further comprise any or all necessary preparative reagents, washing reagents, detection reagents and signal producing reagents commonly known in the art.

In all of these assays and methods, a number of distinct peptides or antibodies may be used, either sequentially or simultaneously, and differently labelled, in order to detect a number of different PoERV types in a single assay.

Diagnostic assays based upon the present invention may be used to determine the presence or absence of POERV infection, and the POERV type involved.

10

15

20

25

q

In an assay for the diagnosis of viral infection, there are basically three distinct approaches that can be adopted, involving the detection of viral nucleic acid, viral antigen or viral antibody respectively. nucleic acid is generally regarded as the best indicator of the presence of the virus itself and would identify materials likely to be infectious. However, the detection of nucleic acid is not usually as straightforward as the detection of antigens or antibodies since the level of target can be very low. Viral antigen is used as a marker for the presence of virus and as an indicator of infectivity. Depending upon the virus, the amount of antigen present in a sample can be very low and difficult to detect. Antibody detection is relatively straightforward because, in effect, the host immune system is amplifying the response to an infection by producing large amounts of circulating antibody. The nature of the antibody response can often be clinically useful, for example IgM rather than IgG class antibodies are indicative of a recent infection, or the response to a particular viral antigen may be associated with clearance of the virus. Thus the exact approach adopted for the diagnosis a viral infection depends upon the particular circumstances and the information sought. In the case of PoERV. a diagnostic assay may embody any one or a combination of these three approaches.

5

10

15

20

25

PCT/GB00/03159

10

In an assay for the diagnosis of PoERV involving detection of viral antigen or antibody, the method may comprise contacting a test sample with a peptide of the present invention or a polyclonal or monoclonal antibody against the peptide and determining whether there is any antigen-antibody binding contained within the test sample. For this purpose, a test kit may be provided comprising a peptide, as defined herein, or a polyclonal or monoclonal antibody thereto and means for determining whether there is any binding with antibody or antigen respectively contained in the test sample to produce an immune complex. The test sample may be taken from any appropriate tissue or physiological fluid, such as blood (e.g. serum or plasma), saliva, urine, cerebrospinal fluid, sweat, tears or tissue exudate. If a physiological fluid is obtained, it may optionally be concentrated for any viral antigen or antibody present.

A variety of assay formats may be employed. The peptide can be used to capture selectively antibody against POERV from solution, to label selectively the antibody already captured, or both to capture and label the antibody. In addition, the peptide may be used in a variety of homogeneous assay formats in which the antibody reactive with the peptide is detected in solution with no separation of phases.

The types of assay in which the peptide is used to capture antibody from solution involve immobilization of the peptide on to a solid surface. This surface should be

5

10

15

20

25

PCT/CR00/03159

11

capable of being washed in some way. Examples of suitable surfaces include polymers of various types (moulded into microtitre wells; beads; dipsticks of various types; aspiration tips; electrodes; and optical devices), particles (for example latex; stabilized red blood cells; bacterial or fungal cells; spores; gold or other metallic or metal-containing sols; and proteinaceous colloids) with the usual size of the particle being from 0.02 to 5 microns, membranes (for example of nitrocellulose; paper; cellulose acetate; and high porosity/high surface area membranes of an organic or inorganic material).

The attachment of the peptide to the surface can be by passive adsorption from a solution of optimum composition which may include surfactants, solvents, salts and/or chaotropes; or by active chemical bonding. Active bonding may be through a variety of reactive or activatable functional groups which may be exposed on the surface (for example condensing agents; active acid esters, halides and anhydrides; amino, hydroxyl, or carboxyl groups; sulphydryl groups; carbonyl groups; diazo groups; or unsaturated groups). Optionally, the active bonding may be through a protein (itself attached to the surface passively or through active bonding), such as albumin or casein, to which the viral peptide may be chemically bonded by any of a variety of methods. The use of a protein in this way may confer advantages because of isoelectric point, charge, hydrophilicity or other physico-chemical property. viral peptide may also be attached to the surface (usually

PCT/CR00/03159

WO 01/12816

5

10

15

20

25

12

but not necessarily a membrane) following electrophoretic separation of a reaction mixture, such as immunoprecipitation.

After contacting the surface bearing the peptide with a test sample (in the presence of a blocking mixture if required), allowing time for reaction, and, where necessary, removing the excess of the sample by any of a variety of means, (such as washing, centrifugation, filtration, magnetism or capillary action) the captured antibody is detected by any means which will give a detectable signal. For example, this may be achieved by use of a labelled molecule or particle as described above which will react with the captured antibody or any molecule containing an epitope contained in the peptide. In one embodiment, it is preferred to add an anti-human IgG conjugated to horseradish peroxidase and then to detect the bound enzyme by reaction with a substrate to generate a colour.

The detectable signal may be produced by any means known in the art such as optical or radioactive or physicochemical and may be provided directly by labelling the molecule or particle with, for example, a dye, radiolabel, fluorescent, luminescent, chemiluminescent, electroactive species, magnetically resonant species or fluorophore, or indirectly by labelling the molecule or particle with an enzyme itself capable of giving rise to a measurable change of any sort. Alternatively the detectable signal may be obtained using, for example, agglutination, or through a

5

10

15

20

25

PCT/GB00/03159

13

diffraction or birefrigent effect if the surface is in the form of particles.

Assays in which a peptide itself is used to label an already captured antibody require some form of labelling of the peptide which will allow it to be detected. labelling may be direct by chemically or passively attaching for example a radiolabel, magnetic resonant species, particle or enzyme label to the peptide; or indirect by attaching any form of label to a molecule which will itself react with the peptide. The chemistry of bonding a label to the peptide can be directly through a moiety already present in the peptide, such as an amino group, or through an intermediate moiety, such as a maleimide group. Capture of the antibody may be on any of the surfaces already mentioned in any reagent including passive or activated adsorption which will result in specific antibody or immune complexes being bound. particular, capture of the antibody could be by antispecies or anti-immunoglobulin-sub-type, by rheumatoid factor, proteins A, G and the like, or by any molecule containing an epitope contained in the peptide.

The labelled peptide may be used in a competitive binding fashion in which its binding to any specific molecule on any of the surfaces exemplified above is blocked by antigen in the sample. Alternatively, it may be used in a non-competitive fashion in which antigen in the sample is bound specifically or non-specifically to any of the surfaces above and is also bound to a specific bi- or

poly-valent molecule (e.g. an antibody) with the remaining valencies being used to capture the labelled peptide.

Examples of the invention will now be described by way of illustration only, and with reference to the accompanying Figures, in which:

Figure 1 is the consensus amino acid sequence of the POERV GAG protein; Figure 2 is a comparison of amino acid sequences of five different POERV ENV proteins (PERV; PERV A, PERV B, POEV 1; Galbraith et al., 1997: PERV MSL, Tsukuba; Fishman, 1997) and Figure 3 is a comparison of amino acid sequences of the variable region of five different POERV ENV proteins, showing the six different ENV peptides (peptides D-H and J) referred to in the following examples.

METHODS

5

10

15

20

25

Preparation of PoERV virions.

Human 293 cells (American Type Culture Collection [ATCC] # CRL1573) and Raji cells (ATCC # CCL 86) were infected with PoERV by exposure to polybrene (Sigma-Aldrich Co. Ltd.) and continued incubation with cell-free filtered supernatant from PK-15 (ATCC # CCL 33) cells previously shown to be infected with all three subgroups of PoERV. The 293 cells allow replication of type B PoERV (POEV-1). The 293 cells were shown to be infected after passage by measurement of the reverse transcriptase activity of the cell supernatant and by a PoERV GAG-specific Polymerase Chain Reaction (PCR). The resulting virus particles were isolated from the cell line supernatant as follows.

5

20

25

PCT/GB00/03159

15

Supernatant from exponentially growing cells was layered onto a 20/40% (w/v) discontinuous sucrose density gradient and centrifuged at 100,000 g for 150 min. The viral material at the sucrose interface was harvested, and viral particles pelleted by further ultracentrifugation at 100,000g for 60 min, followed by resuspension in DMEM (Life Technologies Ltd., UK).

Control retroviruses

To provide retroviral controls for cross reactivity with POERV GAG and ENV, Squirrel monkey retrovirus, Murine leukaemia virus, Maedi-Visna virus and Equine infectious anemia virus virions were prepared from the appropriate infected cell line as described by Shepherd and Smith (1999).

Selection and preparation of GAG peptides

Peptides from the GAG protein can provide a capture antigen and a means to generate positive control antisera. The antisera can be directed against conserved polypeptides present in the PoERV virion core likely to induce an immune response in recipients of the virus. These reagents would be useful diagnostic tools for immunosurveillance of recipients of porcine material or tissues for exposure to PoERV. Therefore, peptides encompassing potential antigenic regions of PoERV GAG were selected from the translated amino-acids derived from the sequence of the gag region of PoERV based on three criteria; hydrophilicity,

10

15

20

2.5

PCT/GB00/03159

16

potential B-turns and K, D, R and E charged residues. The regions were identified using Hopp and Woods hydropathicity (1981) scale and Kyte and Doolittle (1982) hydrophobicity scale.

For GAG two peptides were identified as potential antigens. Peptide 1 was from the C-terminus of p30-GAG at residue 437-451 of the polypeptide, nucleotides 1896-1940 of the gag open reading frame (ORF). Peptide 2 was from the start of the p10 segment of the GAG polypeptide at residue 502-515 of the polypeptide, nucleotides 2091- 2132 of the gag ORF. The peptides shown below were chemically synthesised by Genosys Biotechnologies Inc.

Peptide 1: (C) REERRDRRQEKNLTK

Peptide 2: (W) ARNCPKKGNKGPKS

The bracketed amino-acid is not in sequence - 5' position is from next residue (R).

These peptides, and the GAG consensus polypeptide sequence, are shown in Figure 1.

A BLAST search (Altschui et al., 1997) of the non-redundant GenBank coding sequences with GAG peptide 1 showed homology with seven sequences all from the gag ORF. Of the seven, three were with PoERV sequences with accessions gi 3116446 (100% match), emb CAA7651 (100% match), gi 3116442 (86% match). The remainder were against the closely related Gibbon ape leukaemia virus (gi 3033415, 92% match) and Simian sarcoma virus (gp P03330, 86% match).

5

10

15

20

25

PCT/GB00/03159

17

The remaining two sequences were from murine viruses, including a virus from Rattus norvegicus (emb CAA24514; 92% match), and one against Mus dunni endogenous retrovirus (gi 3309124, 93% match). A similar BLAST search with GAG peptide 2 showed 100 - 99% homology with only the PoERV sequences listed above.

Selection and Preparation of PoERV ENV peptides

We have previously identified and derived the nucleotide sequence of a unique PoERV type capable of infecting human cells (Galbraith, 1997). Furthermore, it has been shown that the amino acid sequence of the ENV region of various PoERV types contains both conserved and non-conserved regions (Galbraith, 1997; Figure 2). In order to exploit these differences to produce immunological reagents to allow the identification of the type of PoERV giving rise to an immunological reaction in a patient, PoERV-type-specific ENV peptides and antisera were generated.

Six peptides, D-H and J, were identified as potential antigens. The peptides are shown below and their position in the *env* ORF of the various PoERV types is shown in Figure 3. The peptides were chemically synthesised by the University of Glasgow Veterinary Pathology Department.

Peptide D: TSLRPDITOPPSNSTT

Peptide E: KGKQENIQKWINGMS

Peptide F: RKTGKYSKVDKWYELGNS

Peptide G: NTVLTGQRPPTQ

PCT/GB00/03159

18

Peptide H: GHGRWKDWQQRVQKDVRNKQIS

Peptide J: IQEQRPSPNPSDYNTT

The amino acid residues of all peptides are identified by the standard one letter abbreviations.

Preparation of recombinant PoERV p30-GAG and ENV polypeptides

In addition to the peptide reagents more general PoERV p30-GAG and an abbreviated ENV polypeptides were designed and produced for use as capture antigens and to produce antipolypeptide sera. The required polypeptide portions of the gag and env genes were produced by PCR amplification, molecularly cloned into a prokaryotic expression vector and expressed as described below using standard techniques (Maniatis et al, 1982).

PoERV p30-GAG

A fragment encompassing the p30 region of the gag ORF from nucleotide 1173-1949 of the PoERV genome (Galbraith et al, 1997; Gene Bank Accession # A66553) was amplified by PCR from cDNA generated from PK15 mRNA using ligation independent cloning oligonucleotide primers (pET-32 Ek/LIC cloning and expression vector; Novagen Inc. Catalogue # 69076-3). The oligonucleotides were:

20

10

15

SOOKOL SAGRAGUL

5

10

15

20

25

PCT/GB00/03159

19

p30 forward 5' GAC GAC GAC AAG CTG CGC ACC TAT GGC C 3'
p30 reverse 5' GAG GAG AAG CCC GGG TCT AGG CCA AGA TCT

TAG TCA AAT TCT TCT C 3'

The nucleotides in bold are viral specific.

The PCR conditions were 30 cycles of 95°C for 1 min, 58°C for 1 min and 72°C for 1 min. The resulting 776 base pair fragment was molecularly cloned into the appropriate LIC site of the pET-32 LIC vector following the manufacturer's instructions (Novagen Inc. 69076-3 instruction manual), transfected into competent Novoblue^M Escherichia coli cells and plated on solid LB medium containing ampicillin. The transformed colonies were selected by resistance to ampicillin.

POERV ENV

A fragment encompassing the region of the env ORF from nucleotide 5616- 6304 of the PoERV genome (Galbraith et al,1997; Gene Bank Accession # A66553) was amplified by PCR from cDNA generated from PK15 and PoERV-infected 293 cells (PoERV B) mRNA using ligation independent cloning oligonucleotide primers (PET-32 Ek/LIC cloning and expression vector; Novagen Inc. Catalogue # 69076-3). The oligonucleotides were:

env forward 5' GAC GAC GAC AAG ATC CAT GCA TCC CAC GTT

PCT/GR00/03159

20

env reverse 5' GAG GAG AAG CCC GGT CTC TAT CCT AAG GCG

The nucleotides in bold are viral specific.

5

10

15

20

25

The PCR conditions were 30 cycles of 95°C for 1 min, 60°C for 1 min and 72°C for 1 min. The resulting 688 base pair fragment was molecularly cloned into the appropriate LIC site of the pET-32 LIC vector following the manufacturer's instructions as described above.

For expression from the T7 promoter the recombinants are required to be transferred to a host with T7 polymerase activity. To this end plasmid DNA was isolated from the ampicillin resistant NovoblueTM clones carrying the gag or env fragment in the correct orientation for expression as determined by restriction endonuclease mapping. The plasmid DNAs were each transfected into competent E. coli AD494 (DE3) trx B-.

For screening for the production of recombinant protein, two ml cultures of *E. coli* transformed with either of the two expression constructs were grown with shaking at 37° C to late log phase (O.D.600mm of approximately 0.6) and induced by the addition of Isopropylthio-beta-galactoside (IPTG) to 0.1 mM. Induced cultures were then incubated for a further 2 h after which the bacteria were collected by centrifugation. The bacterial pellet was lysed by boiling in SDS-PAGE sample buffer and the protein profile of the induced bacteria was analysed on a 12% acrylamide gel

5

10

15

20

PCT/GB00/03159

21

followed by staining with coomasie brilliant blue dye. (Laemmli, 1970; Gallagher, 1997).

Large scale preparations of purified GAG and ENV polypeptides were made according to the manufacturer's instructions (Novagen Inc. Catalogue # 69076-3).

Preparation of antisera to whole virions, peptides and recombinant F30-GAG and ENV antigens.

For GAG peptide 1 and peptide 2, the peptides were conjugated with keyhole limpet hemacyanin carrier protein and each of two rabbits was inoculated six times at fourteen day intervals. The animals were bled out at day seventy seven after the first inoculation. The p30-GAG polypeptide was inoculated three times at fourteen day intervals into a rabbit. The animal was bled out at day seventy seven.

For ENV peptides D-H and J, the peptides were conjugated with keyhole limpet hemacyanin carrier protein and one sheep was inoculated three times at twenty eight day intervals. The ENV polypeptide was inoculated three times at fourteen day intervals into a rabbit.

Virions purified from PK15 cells were inoculated three times at fourteen day intervals into each of two guinea pigs.

5

10

15

PCT/GB00/03159

21

followed by staining with coomasie brilliant blue dye. (Laemmli, 1970; Gallagher, 1997).

Large scale preparations of purified GAG and ENV polypeptides were made according to the manufacturer's instructions (Novagen Inc. Catalogue # 69076-3).

Preparation of antisera to whole virions, peptides and recombinant P30-GAG and ENV antigens.

For GAG peptide 1 and peptide 2, the peptides were conjugated with keyhole limpet hemacyanin carrier protein and each of two rabbits was inoculated six times at fourteen day intervals. The animals were bled out at day seventy seven after the first inoculation. The p30-GAG polypeptide was inoculated three times at fourteen day intervals into a rabbit. The animal was bled out at day seventy seven.

For ENV peptides D-H and J, the peptides were conjugated with keyhole limpet hemacyanin carrier protein and one sheep was inoculated three times at twenty eight day intervals. The ENV polypeptide was inoculated three times at fourteen day intervals into a rabbit.

Virions purified from PK15 cells were inoculated three times at fourteen day intervals into each of two guinea pigs.

20

5

10

15

20

25

PCT/GB00/03159

22

Indirect immunofluorescence staining

To test the specificity of the p30-GAG antisera the method outlined by Riggs (1989) was used. PoERV-infected Raji cells and uninfected control Raji cells were fixed and tested for indirect immunofluorescence with anti p30-GAG using a fluorescein isothiocyanate (FITC) labelled antirabbit detector antibody. The cells were examined by fluorescence microscopy.

Preparation of Western blot membranes

Recombinant p30-GAG polypeptide and ENV polypeptide were prepared, harvested and purified from an E.coli vector. The recombinant proteins were tested to determine appropriate dilution of protein which yielded a positive result in the immunoassay. In addition, extracts from PoERV-infected 293 cells, PoERV-infected Raji cells or purified PoERV virions were used as antigens. To obtain specific and reproducible Western blot assays, a number of parameters were required to be optimised for each assay, such as: Primary antibody dilution, incubation time, incubation temperature, secondary antibody dilution, incubation time, incubation temperature, washing buffers, developing reagents. blocking/dilution buffers, Recombinant polypeptides were added to nine wells of a ten lane 12% Tris/glycine acrylamide gel. Molecular weight markers were added to the first lane. The samples were electrophoresed and the gel electroblotted to a poly vinvlidene fluoride (PVDF) membrane. (Gallagher et al,

PCT/GB00/03159

23

1997). The membrane was cut into strips each strip containing one lane of recombinant protein. These strips were used as the basis of the assay.

5 Preparation dilutions of antisera

Samples were prepared in a Class 2 safety cabinet or other clean environments.

A typical negative control was prepared by making up to a 1:200 dilution of normal sera in blocking reagent.

A typical positive control was prepared by making a 1: 500, 1: 1000 or greater dilution of anti-PoERV p30-GAG polypeptide, peptide serum or anti - recombinant ENV serum.

15

20

25

10

A typical test serum was prepared by making up to a 1:200 dilution of sera.

Preparation of Western blotting membranes and POERV antibody detection.

To block non-specific binding sites membrane strips each were placed in a 15 ml centrifuge tube and 2 ml blocking reagent (2.5 g skimmed dried milk in 50 ml PBS/ 0.5% v/v Tween-20²⁰) added. The strips were placed on a rotary shaker such that the strip moved slightly on each revolution and were incubated for 30 min at ambient

5

10

15

20

25

PCT/GB00/03159

24

temperature. The blocking reagent was removed and replaced with 5-10 μ l of the diluted serum. The membrane was incubated with shaking for 1 h at ambient temperature. To stop incubation the strip was removed from diluted serum and placed into PBS/ Tween-20TM and washed with three changes of PBS/ Tween-20TM at ambient temperature with shaking.

The appropriate species specific secondary antiserum conjugated to alkaline phosphatase was used as detector e.g. if human serum was being tested, an anti-human IqG alkaline phosphatase (AP) conjugate was used. The p30-GAG positive control required anti-rabbit IgG AP conjugate for detection and the anti ENV required anti-sheep IgG AP conjugate. The detection was done as follows; each strip was placed in an unused 15 ml centrifuge tube, 2 ml of 1:1000 dilution of secondary sera in blocking reagent was added and incubated with shaking at ambient temperature for 1 h. The strip was removed from the centrifuge tube, placed in PBS/Tween-20th and washed with 3 changes of PBS/Tween-20™, at ambient temperature with shaking. The strips were then put into a 15 ml centrifuge tube and 2 ml of bromochlorindoyl phosphate/ nitroblue tetrazolium (BCIP/NBT, Sigma-Aldrich Co. Ltd.) solution was added to each tube. The strips were shaken gently and allowed to develop for 5 min. The reaction was stopped by rinsing the membrane strip in purified water and the strips were removed from the water and allowed to air dry.

5

10

15

20

25

PCT/GB00/03159

25

ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) Antiqen coating of microtiter plates

50 µl of antigen (either recombinant p30-GAG, extracts from PoERV-infected 293 cells or purified PoERV B virions) were diluted to the required concentration in carbonate-bicarbonate coating buffer (Sigma-Aldrich Co. Ltd.) was added to wells of a 96 well, flat bottomed microtiter ELISA plate (Dynex Immulon 2). Some wells contained carbonate-bicarbonate coating buffer only and some were left blank to act as controls for non-specific binding. The plate was covered with a plate seal and incubated at 4°C for approximately 16 h. The unbound antigen and coating solution were then removed from the wells with a pipette and washed three times with PBS / 0.05% Tween-20^{5M}. Any remaining PBS / 0.05% Tween-20^{5M} was removed by blotting on a tissue.

Blocking of microtiter plates

50 µl of fresh blocking buffer (5% (w/v) skimmed milk /PBS / 0.05% Tween-20TM) was added to each antigen coated well and control well. The plate was covered with a plate seal and incubated at ambient temperature in an humidified chamber for 1 h. The blocking buffer was removed and the plate wells washed three times with PBS / 0.05% Tween-20TM and any remaining PBS / 0.05% Tween-20TM was removed by blotting on a tissue.

PCT/GR00/03159

26

Incubation with primary antibody

50 ul of negative control sera, test sera, and positive control sera at the experimental dilution were added to the antigen coated wells and the plates covered with a plate seal and incubated at ambient temperature for approximately 1 h in an humidified chamber. Following incubation all sera were removed using a pipette and the plate wells washed three times with PBS / 0.05% Tween-20th, any remaining PBS / 0.05% Tween-20™ was removed by blotting on a tissue.

10

15

20

25

5

Incubation and development with peroxidase-conjugated secondary antibody

50 μ l of a 1:500 dilution of species specific peroxidase conjugated secondary antibody in blocking buffer was added to each antigen coated well. For human serum an anti-human IqG peroxidase conjugate was used. The p30-GAG positive control required anti-rabbit IgG peroxidase conjugate for detection and the anti ENV required anti-sheep IgG peroxidase conjugate. The plates were covered with a plate seal and incubated at ambient temperature for approximately 1 h in an humidified chamber. Following incubation the conjugate was removed using a pipette and the plate wells washed three times with PBS / 0.05% Tween-20™. Any remaining PBS / 0.05% Tween-20th was removed by blotting on a tissue.

The substrate was prepared as follows: one 0phenylenediamine tablet (Sigma-Aldrich Co. Ltd.) and one $urea/H_2O_2$ tablet were dissolved in 20 ml of purified water.

10

15

20

25

PCT/GB00/03159

27

An aliquot of 50 μ l of substrate was added to each well and the plate incubated at ambient temperature in the dark for 30 min. The reaction was then stopped by adding 50 μ l of 3N Hcl or 3 M $\rm H_2SO_4$ to each well. The colour development in the wells was measured at 490 nm using a Dynex MRX microplate reader.

For alkaline phosphatase conjugated secondary antibodies the substrate used was p-Nitrophenyl phosphate (pNPP; Sigma-Aldrich Co. Ltd.) and the plates were read at 405 nm.

Electron Microscopy

Negative stain electron microscopy (NSEM) (Doane, 1980) was used to identify the presence of PoERV virions. Supernatant from PoERV-infected pK15 cells was layered onto a 20/40% sucrose density gradient (w/v) discontinuous centrifuged at 100,000 g for 150 min. The viral material at the sucrose interface was harvested, and viral particles pelleted by further ultracentrifugation at 100,000g for 60 min, followed by resuspension in DMEM (Life Technologies Ltd.). The sample was then applied to pioloform-coated copper 300 mesh EM grids and allowed to air dry. Grids were fixed with 2.5% glutaraldehyde (Agar Scientific), stained with 5% uranyl acetate (Agar Scientific) and allowed to air dry. Grids were examined on a Philips EM-400 transmission electron microscope.

PCT/GB00/03159

28

Immuno- Electron Microscopy

The immunostaining was done following the method of Marshall et al (1992). Briefly, NSEM samples were applied to pioloform-coated nickel 300 mesh EM grids and allowed to air dry. Grids were fixed with modified immunofix, post fixed with 0.5 M NH₄Cl, then incubated with 2% bovine serum albumin (Sigma-Aldrich Co. Ltd.). Samples were then incubated with rabbit anti-POERV (rabbits immunised with whole POERV) or rabbit anti-POERV p30-GAG antibody, washed in modified immunobuffer followed by incubation with anti-rabbit IgG gold conjugate (Sigma-Aldrich Co. Ltd.). Grids were stained with 5% uranyl acetate, and allowed to air dry. Samples were visualised on a Philips EM-400 transmission electron microscope.

15

10

5

EXAMPLE ONE

Indirect immunofluorescence staining of PoERV-infected cells.

20 Viral specific fluorescence was observed in PoERV-infected Raji cells using the anti p30-GAG antiserum. No immunofluorescence was seen with the negative control Raji cells.

PCT/GB00/03159

29

EXAMPLE TWO

Western Blotting for Antibodies to POERV GAG

Anti-GAG peptide 1 antisera and sera from rabbits inoculated with the recombinant p30-GAG polypeptide detected the expected protein of approximately 30kd in extracts of PoERV-infected 293 or PoERV-infected Raji cells, purified PoERV virions and recombinant p30-GAG. The PoERV antibody could be detected at a dilution of 1:1000.

10

15

20

5

No band of equivalent size to the GAG 30 kd polypeptide was detected in uninfected control cells.

No band of equivalent size to the GAG 30 kd polypeptide was detected against the following purified retroviruses:

Squirrel monkey retrovirus
Murine leukaemia virus
Maedi-Visna virus
Equine infectious anemia virus

Therefore, the positive control antisera were specific for PoERV.

25 Determination of assay specificity using Serum Panels Normal human sera

On testing of 90 normal serum samples from healthy individuals, whose blood was taken for occupational health

5

10

PCT/GB00/03159

30

reasons, no PoERV reactive antibody was detected in any of the sera.

Normal primate sera

On testing 42 normal serum samples from healthy primates no PoERV reactive antibody was detected. There was no cross-reactivity with sera from normal primates.

Cardiac transplant patient sera

On testing 20 serum samples from individuals who had received a cardiac transplant in the preceding 36 months no PoERV reactive antibody was detected. There was no cross-reactivity with sera from patients who had been immunosupressed.

HIV positive sera

On testing 13 serum samples from individuals positive for the presence of antibody to HIV no PoERV reactive antibody was detected. There was no cross-reactivity with sera from patients infected with a human Lentivirus.

20 HTLV positive sera

On testing 10 serum samples from individuals positive for the presence of antibody to HTLV-1 virus no PoERV reactive antibody was detected. There was no cross-reactivity with sera from patients infected with a human Gammaretrovirus.

PCT/GB00/03159

31

Butchers with acute lymphoblastic leukaemia (ALL)

On testing 3 serum samples from butchers with ALL no POERV reactive antibody was detected. There was no cross-reactivity with sera from patients with assumed prolonged exposure to PoERV and PoERV antigens with a leukaemic disorder.

EXAMPLE THREE

ELISA p30-GAG

A titration of p30-GAG antigen to anti-p30-GAG antisera gave a significant signal at 1:250600 dilution antigen to 1:32000 dilution of antisera. A similar titration of antisera against PoERV virions gave a significant signal at a 1:3200 dilution of both antigen and antisera.

15

20

25

5

10

Normal human sera

On testing of five normal serum samples from healthy individuals whose blood was taken for occupational health reasons, no significant signal was detected in any of the sera against recombinant p30-GAG.

EXAMPLE FOUR

Detection and Visualisation of PoERV Virions by Immuno-Electron Microscopy

Examination of PoERV virion preparations by negative stain revealed particles showing the characteristic size and structure of a Gammaretrovirus of approximately 90-120 nm with a dark inner core and double membraneous outer region.

PCT/GB00/03159

32

The particles bound immuno-gold labeled anti p30-GAG antiserum indicating that the antiserum could be used to visualise PoERV virions by immuno-electron microscopy.

5 EXAMPLE FIVE

10

15

20

ELISA ENV

A titration of antisera raised against ENV peptides D, E, F, G, H, J. to purified PoERV B virions gave a significant signal indicating that the ENV peptides produced a virus-specific reaction in the animals. Peptides D and F, both from PoERV B (POEV1; Figure 2; Galbraith et al, 1997) gave the highest signal.

EXAMPLE SIX

Western Blotting for Antibodies to PoERV ENV

Antisera from guinea pigs inoculated with whole purified PoERV virions from PK15 cells detected the expected recombinant ENV protein of approximately 24 kD in extracts of E.coli expressing the env construct.

No band of equivalent size to the ENV $24~{\rm kD}$ polypeptide was detected on E.coli control cells without the expression construct.

PCT/GB00/03159

33

REFERENCES

Altschui SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W and Lipman DJ (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Research, 25: 3389-3402.

Doane FW . (1980). Virus morphology as an aid for rapid diagnosis. Yale Journal of Biological Medicine, 53, 19-25.

10

5

Ekins RP. (1997). Immunoassay design and optimisation. In Principles and Practice of Immunoassay Second Edition. Ed. CP Price and DJ Newman. Macmillan Reference, Ltd. London.

15 Fishman JA. (1997). Patent Application W097/21836.

Galbraith DN. Haworth C, Lees GM, and Smith KT. (1997).
Patent Application W097/40167.

- 20 Gallagher S. (1997). One-dimensional SDS gel electrophoresis of proteins. In Current Protocols in Molecular Biology. 10.2.2-10.2.35. John Wiley & Sons, Inc. USA.
- 25 Gallagher S, Winston SE, Fuller SA and Hurrell JGR. (1997). Immunoblotting and immunodetection. In Current Protocols in Molecular Biology. 10.8.1-10.8.21. John Wiley & Sons, Inc. USA.

34

Hopp TP and Woods KR. (1981). Prediction of protein antigenic determinants from amino acid sequences. Proceeding of the National Academy of Sciences USA, 78, 3824-3828.

5

Kyte J and Doolittle RF. (1982). A simple method for displaying the hydropathic character of a protein. Journal of Molecular Biology, 157, 105-132.

10

Laemmli UK. 1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.

15

Maniatis T, Fritsch EF and Sambrook J. (1982). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

20

Marshall GE, Kontas AG, Reid GG, Edwards JG and Lee WR. (1992). Type IV collagen and laminin in Bruch's membrane and basal linear deposit in the human macula. British Journal of Ophthalmology, 76, 607-614.

Onions D, Hart D, Mahoney C, Galbraith D and Smith K. (1998). Endogenous retroviruses and the safety of porcine xenotransplantation. Trends in Microbiology, 6, 430-431.

25

Patience C, Takeuchi Y and Weiss R. (1997). Infection of human cells by an endogenous virus of pigs. Nature

PCT/GB00/03159

35

Medicine, 3, 282-286.

Riggs JL. (1989). Immunofluorescence staining. In Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections Sixth Edition. Ed. NJ Schmidt and RW Emmons. 123-133. American Public Health Association Inc. Washington DC.

Strandstrom H, Veijalainen P, Moennig V, Hunsmann G, Schwarz H and Schafer W. (1974). C-type particles produced by a permanent cell line from a leukemic pig. 1. Origin and properties of the host cells and some evidence for the occurrence of C-type particles. Virology, 57, 175-178.

Shepherd AJ and Smith KT. (1999). Viral evaluation of animal cell lines used in biotechnology. In Methods in Biotechnology, Vol. 8: Animal Cell Biotechnology. Ed. N Jenkins. Humana Press, Inc. Totwa New Jersey.

20 Todaro GJ, Benveniste RE, Lieber MM, and Sher CJ. (1974). Characterisation of a type C virus released from the porcine cell line PK (15). Virology, 58, 65-74.

10

PCT/GB00/03159

36

CLAIMS

 A porcine endogenous retrovirus (PoERV) polypeptide fragment, wherein said polypeptide fragment has PoERV specific antigenic or immunogenic activity.

5

 A polypeptide fragment according to claim 1, wherein said polypeptide fragment comprises a fragment of a PoERV GAG polypeptide.

10

 A polypeptide fragment according to claim 2, wherein said polypeptide fragment comprises a fragment of a polypeptide sequence as shown in Figure 1.

4. 15 said

 A polypeptide fragment according to claim 3, wherein said polypeptide fragment comprises the amino acid sequence REERRDRRQEKNLTK.

20

 A polypeptide fragment according to claim 3, wherein said polypeptide fragment comprises the amino acid sequence ARNCPKKGNKGPKV.

6. A polypeptide fragment according to claim 1, wherein said polypeptide fragment comprises a fragment of a POERV ENV polypeptide.

25

7. A polypeptide fragment according to claim 6 wherein said polypeptide fragment comprises a fragment of a polypeptide sequence as shown in Figures 2 or 3.

PCT/GB00/03159

37

8. A polypeptide fragment according to claim 7 wherein said polypeptide fragment comprises a fragment from within a conserved region of the sequences shown in Figures 2 and 3.

5

9. A polypeptide fragment according to claim 7 wherein said polypeptide fragment comprises a fragment from within a non-conserved region of the sequences shown in Figures 2 and 3.

10

10. A polypeptide fragment according to claim 9 wherein said polypeptide fragment comprises an amino acid sequence selected from the sequences of peptides D, E, F, G, H and J as shown in Figure 3.

15

11. A polypeptide fragment according to claim 7 wherein said polypeptide fragment comprises a fragment from within a conserved region of the sequences shown in Figures 2 and 3, and a fragment from within a non-conserved region of the sequences shown in Figures 2 and 3.

20

12. A polypeptide fragment according to claim 1, wherein said polypeptide fragment comprises a fragment of a POERV GAG polypeptide and a fragment of a POERV ENV polypeptide.

25

 An antiserum specific to a polypeptide fragment in accordance with any preceding claim.

PCT/GB00/03159


38

- 14. A PoERV specific antibody or fragment thereof raised against a polypeptide fragment in accordance with any of claims 1 to 12.
- 5 15. Use of an antibody according to claim 14 in the detection of PoERV in a sample.
 - 16. Use of a polypeptide fragment according to any one of claims 1 to 12 in the detection of PoERV antibodies in a sample.
 - 17. An assay kit for use in detection of PoERV in a sample, the kit comprising an antibody in accordance with claim 14.

15

10

- 18. An assay kit for use in detection of PoERV antibodies in a sample, the kit comprising a polypeptide fragment in accordance with any of claims 1 to 12.
- 20 19. Use of an antibody according to claim 14, or a polypeptide fragment according to any one of claims 1 to 12 in therapy or diagnosis.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 22 February 2001 (22.02.2001)

PCT

(10) International Publication Number

- (51) International Patent Classification⁷: C12N 15/49, C07K 14/15, G01N 33/50, C07K 16/10, A61K 39/21
 - 9, (74)
- (21) International Application Number: PCT/GB00/03159
- (22) International Filing Date: 16 August 2000 (16.08.2000)
- (25) Filing Language:

English

- (26) Publication Language:
- English

- (30) Priority Data: 9919604.0
- 18 August 1999 (18.08.1999) GB
- (71) Applicant (for all designated States except US): QUIP TECHNOLOGY LIMITED [GB/GB]; Todd Campus, West of Scotland Science Park, Glasgow G20 0XA (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GALBRAITH, Daniel (GB/GB); 513 Alexandra Parade, Glasgow G31 3EW (GB). KELLY, Helena (GB/GB); Flat 1/2, 19 Kelvindale Gardens, Glasgow G20 8DW (GB). SMITH, Kenneth (GB/GB); 5 Capelrig Lane, Newton Mearns, Glasgow G77 6XZ (GB).

- (74) Agents: MCCALLUM, William, Potter et al.; Cruikshank & Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB).
- (81) Designated States (mational): A.E. A.G., A.L., A.M., A.T., A.U., A.Z. B.A. B.B. G., B.R. By, B.Z., A.C. H.C., C.C., C.C., D.E., D.K., D.M., D.Z., E.E., E.F., G.B., G.D., G.E., G.M., H.R., H.U., D.H.L. B., S.J., P.K.E., K.G., K.R., K.R., K.Z., L.C., L.K., L.S., L.T., L.U., L.V., M.A., M.D., M.G., M.K., M.W., M.X., M.Z., N.O., N.Z. P.L., P.T., RO, R.U., S.D., S.E., S.G., S.I., S.K., S.L., T.J., T.M., T.R., T.T., T.Z. U.A., U.G., W. D.Y., N.Y., U.A., Z.W.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, FT, SE). OAPI patent (BF, BJ, CF, CG, CL, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RETROVIRUS ASSAY

PARRY GAG POLYPEPTIDE SHOWING POSITIONS OF PEPTIDES

MGQTVTPLSSLTLDHWTEVESRAINISVOVKKGPROTFCASEMPTFDVGWFSEGTTNSEILLAUKAITG
TGPGSHPDGBFTLTHWOLAEDPPWYKFRINGFREGTRIALGERKHSAKENEPSSSYLPRRAGAD
LAGTPTCSFTELSSTGCCEGTSAPFGAFVVKGPRAGTRSRGATFERTDELAILFLRTYGFPMFGGQLOF
LOYMPFSSADLYMKTHINFPSEDPORLTGLYSSLMFSIGPTWOLOGQLLGTLFTEFERER LILEARNW
FGADGRFTQLQNEITMGFFLTFDFOWDYNTAEGRESIKITKGALVAGLRGGSRFTNLAVKREVMGGPNFP
SVYLERLBEAFRTFTPFDFSEDAGKSVALAFTGGSALDTRKKGRLSLGLAELGLAELDUTREAKKYVFFR
ETEEKRGEKKGREE-DertdirgehaltkilAAVVEGKSSREREDFRKTRSGPROSGNLGNRTPLDK
DCALYCKEKGRIFFATTOFFDFSHAVKAILAUKAILA

The gag peptides 1 and 2 are shown in lower case bold. Peptide 1: REERRDROEKNLTK; Peptide 2: ARNCPKKGNKGPKV.

(57) Abstract: The present invention relates to polypeptide fragments derived from porcine endogenous retrovirus (PoERV) GAG
and ENV polypeptides, and to their use in detection of PoERV antibodies in a test sample. Also provided are antibodies to GAG
and ENV polypeptides, which may be used to detect PoERV in a sample. Polypeptide sequences are provided which are common to
several strains of PoERV, as are sequences specific to a single PoERV strain.

101/17816 A7

10069082.103002 PCT/GB 00/03158 25.10.2000 10/069082

1/4

MGQTVTTPLSLTLDHWTEVRSRAHNLSVQVKKGPWQTFCASEWPTFDVGWPSEGTFNSEIILAVKAIIFQ
TGPGSHPDQBFYLLTWQDLAEDPPFWVKPWINKPRKPGFRILALGEKNKHSAEKVEPSSSYLPRDRGAAD
LGTPTCSPTFLSSTGCCEGTSAPFGAPVVEGPAAGTRSRRGATPERTDEIAILPLHTYGPPWFGGQLQP
LQYWPFSSADLYWKINHPPFSEDPQRLTGLVESIMFSHQPTWDDCQQLLQTFTTEERERILLEARKNV
PGADGRPTQLQNEIDMGFPLTRPGWDYNTAEGRESLKIYRQALVAGLRGASRPTNLAKVWGGPMEP
PSVFLERIMEAFRRFTFPFDFTSEAQKASVALAFIGGSALDIRKKLQRLEGLQEAELRDLVREAEKVYYRR
ETEEBKEQRKEKEREEreerrdrekhiltkilaAVVEGKSSRERERDFRKIRSGPRQSGNLGNRTPLDK
DCGYCKEKGKHWATNGEWKANKYWLALEEDKD

FIGURE 1

10/069082

2/4

PERVA	MHPTLSRRHLPIRGGKPKRLKIPLSFASIAWFLTLSITPQVNGKRLVDSPNSHKPLSLTW
POEVMSL	MHPTLNRRHLPIRGGKPKRLKIPLSFASIAWFLTLSITSQTNGMRIGDSLNSHKPLSLTW
TSUKUBA	MHPTLSRRHLPIRGGKPKRLKIPLSFASIAWFLTLSITSQTNGMRIGDSLNSHKPLSLTW
PERVB	MHPTLSWRHLPTRGGEPKRLRIPLSFASIAWFLTLTITPQASSKRLIDSSNPHRPLSLTW
POEV1	MHPTLSRRHLPTRGGEPKRLRIPLSFASIAWFLTLTITPQASSKRLIDSSNPHRPLSLTW
	:- ::::
PERVA	LLTDSGTGININSTQGEAPLGTWWPELYVCLRSVIPGLNDQATPPDVLRAYGFYVCPGPP
POEVMSL	LITDSGTGININNTQGEAPLGTWWPDLYVCLRSVIPSLTSPPDILHAHGFYVCPGPP
TSUKUBA	LITDSGTGININNTQGEAPLGTWWPDLYVCLRSVIPSLTSPPDILHAHGFYVCPGPP
PERVB	LIIDPDTGVTVNSTRGVAPRGTWWPELHFCLRLINPAVKSTPPNLVRSYGFYCCPG-T
POEV1	LIIDPDTGVTVNSTRGVAPRGTWWPELHFCLRLINPAVKSTPPNLVRSYGFYCCPG-T
POEVI	*: ***:.::: * ** ****: *: *: ::.*:: :: * * ***
PERVA	NNEEYCGNPQDFFCKQWSCITSNDGNWKWPVSQQDRVSYSFVNNPTSYNQFNYGHGRWKD
POEVMSL	NNGKHCGNPRDFFCKQWNCVTSNDGYWKWPTSQQDRVSFSYVNTYTSSGQFNYLT
TSUKUBA	NNGKHCGNPRDFFCKQWNCVTSNDGYWKWPTSQQDRVSFSYVNTYTSSGQFNYLT
PERVB	EKEKYCGGSGESFCRRWSCVTSNDGDWKWPISLQDRVKFSFVNSGPGKYKVMK
POEV1	EKEKYCGGSGESFCRRWSCVTSNDGDWKWPISLQDRVKFSFVNSGPGKYKMMK
	:: :: * : * :: _*:***** *** * ***.:*:**
PERVA	WQQRVQKDVRNKQISCHSLDLDYLKISFTEKGKQENIQKWVNGISWGIVYYGGSGRKK
POEVMSL	WIRTGSPKCSPSDLDYLKISFTEKGKQENILKWVNGMSWGMVYYGGSGKOP
TSUKUBA	WIRTGSPKCSPSDLDYLKISFTEKGKQENILKWVNGMSWGMVYYGGSGKOP
PERVB	LYKDKSCSPSDLDYLKISFTEKGKQENIQKWINGMSWGIVFYKYGGG-A
POEV1	LYKDKSCSPSDLDYLKISFTERKTGKYSKVDKWYELGNSFLLYGGG-A
10271	. * . ********* . * .:: ** . * : .
	CONTINUE DIFFERENCE DATA LED VICTO DE CONTRA LE CONTRA L
PERVA	GSVLTIRLRIETQMEPPVAIGPNKGLAEQGPPIQEQRP-SPNPSDYNTT
POEVMSL	GSILTIRLKIN-QLEPPMAIGPNTVLTGQRPPTQGPGPSSNIT GSILTIRLKIN-QLEPPMAIGPNTVLTGQRPPTQGPGPSSNIT
TSUKUBA PERVB	GSTLTIRLRIETGTEPPVAVGPDKVLAEQGPPALEPPHNLPVPQLTSLRPDITQPPSNGT
POEV1	GSTLTIRLRIETGTEPPVAMGPDKVLAEQGPPALEPPHNLPVPQLTSLRPDITOPPSNST
10011	** *******
PERVA	SGSVPTEPNITIKTGAKLFSLIQGAFQALNSTTPEATSSCWLCLASGPPYYEGMA
POEVMSL	SGSDPTESNSTTKMGAKLFSLIQGAFQALNSTTPEATSSCWLCLASGPPYYEGMA
TSUKUBA	SGSDPTESSSTTKMGAKLFSLIQGAFQALNSTTPEATSSCWLCLALGPPYYEGMA
PERVB	TGLIPTNTPRNSPGVPVKTGQRLFSLIQGAFQAINSTDPDATSSCWLCLSSGPPYYEGMA
POEV1	TGLIPTNTPRNSPGVPVKTGQRLFSLIQGAFQAINSTDPDATSSCWLCLSSGPPYYEGMA
	: * * * :********** *:****** : .***: **
PERVA	RGGKFNVTKEHRDQCTWGSQNKLTLTEVSGKGTCIGMVPPSHQHLCNHTEAFNRTSESQY
POEVMSL	RRGKFNVTKEHRDQCTWGSQNKLTLTEVSGKGTCIGKVPPSHQHLCNHTEAFNQTSESQY
TSUKUBA	RRGKFNVTKEHRDQCTWGSQNKLTLTEVSGKGTCIGKVPPSHQHLCNHTEAFNQTSESQY
PERVB	KEGKFNVTKEHRNQCTWGSRNKLTLTEVSGKGTCIGKAPPSHQHLCYSTVVYEQASENQY
POEV1	KERKFNVTKEHRNQCTWGSRNKLTLTEVSGKGTCIGKAPPSHQHLCYSTVVYEQASENQY
FOEVI	: *****:**:**:**:*********************
PERVA	LVPGYDRWWACNTGLTPCVSTLVFNQTKDFCVMVQIVPRVYYYPEKAVLDEYDYRYNRPK
POEVMSL	LVPGYDRWWACNTGLTPCVSTLVFNQTKDFCIMVQIVPRVYYYPEKAILDEYDYRNHRQK
TSUKUBA	LVPGYDRWWACNTGLTPCVSTLVFNQTKDFCIMVQIVPRVYYYPEKAILDEYDYRNHRQK
PERVB	LVPGYNRWWACNTGLTPCVSTSVFNQSKDFCVMVQIVPRVYYHPEEVVLDEYDYRYNRPK
POEV1	LVPGYNRWWACNTGLTPCVSTSVFNQSKDFCVMVOIVPRVYYHPEEVVLDEYDYRYNR PK
	*****:*****************************

25.10.2000

3/4

PERVA POEVMSL TSUKUBA PERVB POEV1

PERVA POEVMSL TSUKUBA PERVB POEV1

PERVA POEVMSL TSUKUBA PERVB POEV1

PERVA POEVMSL TSUKUBA PERVB POEV1 IMVLRQQYQGLLSQGETDL IMVLRQQYQSPSSR-EAGR IMVLRQQYQSPSSR-EAGR IMVLRQQYQGLLSQGETDL IMVLRQQYQGLLSQGETDL ******** : *:.

FIGURE 2

10/069082

4/4

PERVA POEVMSL TSUKUBA PERVB POEV1	NNEEYCGNPQDFFCKQWSCITSNDGNWKWPVSQQDRVSYSFVNNPTSYNQFNYghgrwkd NNGKHCGNPRDFFCKQWNCVTSNDGYWKWPTSQQDRVSFSYVNTYTSSGQFNYLT NGKHCGNPRDFFCKQWNCVTSNDGYWKWPTSQQDRVSFSYVNTYTSSGGFNY EKEKYCGGSGESFCRRWSCVTSNDGDWKWPISLQDRVKFSFVNSGPGKYKMMK EKEKYCGGSGESFCRRWSCVTSNDGDWKWPISLQDRVKFSFVNSGPGKYKMMK
PERVA	wqqrvqkdvrnkqisCHSLDLDYLKISFTEKGKQENIQKWVNGISWGIVYYGGSGRKK
POEVMSL	WIRTGSPKCSPSDLDYLKISFTEKGKQENILKWVNGMSWGMVYYGGSGKQP
TSUKUBA	WIRTGSPKCSPSDLDYLKISFTEKGKQENILKWVNGMSWGMVYYGGSGKQP
PERVB	LYKDKSCSPSDLDYLKISFTEkgkqeniqkwingmsWGIVFYKYGGG-A
POEV1	LYKDKSCSPSDLDYLKISFTErktgkyskvdkwyelgnsFLLYGGG-A
PERVA	GSVLTIRLRIETQMEPPVAIGPNKGLAEQGPPiqeqrp-spnpsdyntt
POEVMSL	GSILTIRLKIN-QLEPPMAIGPNTVLTGQRPPTQGPGPSSNIT
TSUKUBA	GSILTIRLKIN-QLEPPMAIGPntvltgqrpptqGPGPSSNIT
PERVB	GSTLTIRLRIETGTEPPVAVGPDKVLAEQGPPALEPPHNLPVPQLTSLRPDITQPPSNGT
POEV1	GSTLTIRLRIETGTEPPVAMGPDKVLAEQGPPALEPPHNLPVPQLtslrpditqppsnst
PERVA	SGSVPTEPNITIKTGAKLFSLIQGAFQALNSTTPEATSSCWLCLASGPPYYEGMA
POEVMSL	SGSDPTESNSTTKMGAKLFSLIQGAFQALNSTTPEATSSCWLCLASGPPYYEGMA
TSUKUBA	SGSDPTESSSTTKMGAKLFSLIQGAFQALNSTTPEATSSCWLCLALGPPYYEGMA
PERVB	TGLIPTNTPRNSPGVPVKTGQRLFSLIQGAFQAINSTDPDATSSCWLCLSSGPPYYEGMA
POEV1	TGLIPTNTPRNSPGVPVKTGQRLFSLIQGAFQAINSTDPDATSSCWLCLSSGPPYYEGMA

FIGURE 3



ATTORNEY DOCKET NO. 9013.43

DECLARATION, POWER OF ATTORNEY AND PETITION

As the below named inventor, I hereby declare:

my residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an
iginal, first and joint inventor (if plural names are listed below) of the subject matter which is
 nimed and for which a patent is sought on the invention entitled
RETROVÎRUS ASSAY, the specification of which
[] is attached hereto.
[X] was filed on <u>Feb. 15, 2002</u> ,
as Application Serial No. 10/069,082
and was amended on(if applicable).
[X] was described and claimed in PCT International Application No. PCT/GB00/03159
and as amended under PCT Article 19 on (if any).
· · ·

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent & Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM UNDER 35 USC § 119(a)-(d)

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign applications(s) for patent or inventor's certificate, or §365(a) of any PCT International Applications designating at least one country other than the U.S. listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT International Applications designating at least one country other than the U.S. having a filing date before that of the application on which priority is claimed:

- [] no such applications have been filed
- [X] application(s) listed below:

PRIOR FOREIGN APPLICATIONS(S) Filed Within Twelve Months (Six Months For Design) Of This Application

9919604.0 (Number)	United King (Country)	gdom 18 August 1999 (Day/month/year filed)	PRIOF YES [X]	NO []
(Number)	(Country)	(Day/month/year filed)	[]	[]
(Number)	(Country)	(Day/month/year filed)	[]	[]
CLAIM FO	OR BENEFIT O	PROVISIONAL APPLICATION	UNDER 35	USC §119(e)
I herel	by claim the ben	efit under Title 35. United States	Code 8119(e	of any United

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States Provisional application listed below:

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT International Application(s) designating the U.S. listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the U.S. Patent & Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(App. Serial No.)	(Filing date)	(Status) (patented, pending, abandoned)
(App. Serial No.)	(Filing date)	(Status) (patented, pending, abandoned)

PRIOR FOREIGN APPLICATIONS (Filed More Than Twelve Months (Six Months for Design) Prior To This Application

(Number)	(Country)	(Day/month/year filed)
(Number)	(Country)	(Day/month/year filed)
(Number)	(Country)	(Day/month/year filed)

POWER OF ATTORNEY

And I hereby appoint the practitioners associated with the Customer Number provided below as my attorneys, to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20792

Send correspondence to:

Kenneth D Sibley

Myers Bigel Sibley & Sajovec

Post Office Box 37428 Raleigh, NC 27627

Direct telephone calls to:

Kenneth D Sibley (919) 854 1400

Facsimile:

(919) 854 1401

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

	Full name of sole or first inventor	Daniel GALBRAITH
	× Wellbach	×
_	Inventor's signature	
\mathcal{U}	Date 3 10 02 Citizenship Brit	ish
	Residence Glasgow, United Kingdon	n_GBX
	Post Office Address 513 Alexandra Par	ade, Glasgow, G31 3EW, United Kingdom
	Full name of second, joint inventor, if any	Helena KELLY
	X Helina T. Kly	\prec
)	Inventor's signature	
de	Date 4th Ochbar 2002 Citizenship Britis	sh
	Residence Glasgow, United Kingdo	m GBX
	Post Office Address Flat ½, 19 Kelvindal	e Gardens, Glasgow, G20 8DW, United Kingdom
	Full name of third, joint inventor, if any_	Kenneth SMITH
	V houle /	E X
^	Inventor's signature	
ϕ	Date HOdolog 2002 Citizenship Britis	sh
)	Residence Glasgow, United Kingdo	mGBX
,	Post Office Address 5 Capelrig Lane, New	ton Mearns, Glasgow, G77 6XZ, United Kingdom

O I PILL STATE

SEQUENCE LISTING

Quip Technology Limited

<120> Retrovirus Assay

<130> P10890US

<140> US 10/069,082

<141> 2000-08-16

<150> GB 9919604.0

<151> 1999-08-18

<150> PCT/GB00/03159

<151> 2000-08-16

<160> 19

<170> PatentIn version 3.1

<210>

<211> 524

<212> PRT

<213> porcine endogenous retrovirus

<400> 1

Met Gly Gln Thr Val Thr Pro Leu Ser Leu Thr Leu Asp His Trp 1 10

Thr Glu Val $\underset{20}{\text{Arg}}$ Ser $\underset{20}{\text{Arg}}$ Ala $\underset{25}{\text{His}}$ Asn Leu Ser Val Gln Val Lys Lys

Gly Pro Trp Gln Thr Phe Cys Ala Ser Glu Trp Pro Thr Phe Asp Val ${45\atop 35\atop }$

Gly Trp Pro Ser Glu Gly Thr Phe Asn Ser Glu Ile Ile Leu Ala Val

Lys Ala Ile Ile Phe Gln Thr Gly Pro Gly Ser His Pro Asp Gln Glu Pro Tyr Ile Leu Thr Trp Gln Asp Leu Ala Glu Asp Pro Pro Pro Trp $85 \hspace{0.5cm} 90 \hspace{0.5cm} 95$ Val Lys Pro Trp Leu Asn Lys Pro Arg Lys Pro Gly Pro Arg Ile Leu 100 105 110 Ala Leu Gly Glu Lys Asn Lys His Ser Ala Glu Lys Val Glu Pro Ser Ser Ser Tyr Leu Pro Arg Asp Arg Gly Ala Ala Asp Leu Ala Gly Thr 130 135 140 Pro Thr Cys Ser Pro Thr Pro Leu Ser Ser Thr Gly Cys Cys Glu Gly 145 150 155 160 Thr Ser Ala Pro Pro Gly Ala Pro Val Val Glu Gly Pro Ala Ala Gly Thr Arg Ser Arg Arg Gly Ala Thr Pro Glu Arg Thr Asp Glu Ile Ala 180 185 190 Ile Leu Pro Leu Arg Thr Tyr Gly Pro Pro Met Pro Gly Gly Gln Leu 195 200 205 Gln Pro Leu Gln Tyr Trp Pro Phe Ser Ser Ala Asp Leu Tyr Asn Trp 210 215 220 Lys Thr Asn His Pro Pro Phe Ser Glu Asp Pro Gln Arg Leu Thr Gly 225 230 235 Leu Val Glu Ser Leu Met Phe Ser His Gln Pro Thr Trp Asp Asp Cys Gln Gln Leu Leu Gln Thr Leu Phe Thr Thr Glu Glu Arg Glu Arg Ile 260 265 270 Leu Leu Glu Ala Arg Lys Asn Val Pro Gly Ala Asp Gly Arg Pro Thr Gln Leu Gln Asn Glu Ile Asp Met Gly Phe Pro Leu Thr Arg Pro Gly 290 295 300 Trp Asp Tyr Asn Thr Ala Glu Gly Arg Glu Ser Leu Lys Ile Tyr Arg 305 310 315 Gln Ala Leu Val Ala Gly Leu Arg Gly Ala Ser Arg Arg Pro Thr Asn 325 330 335 Leu Ala Lys val Arg Glu val Met Gln Gly Pro Asn Glu Pro Pro Ser 340 345 350

Val Phe Leu Glu Arg Leu Met Glu Ala Phe Arg Arg Phe Thr Pro Phe 355 360 365 Asp Pro Thr Ser Glu Ala Gln Lys Ala Ser Val Ala Leu Ala Phe Ile $370 ext{ } 375 ext{ } 380 ext{ }$ Gly Gln Ser Ala Leu Asp Ile Arg Lys Lys Leu Gln Arg Leu Glu Gly 385 390 395 Leu Gln Glu Ala Glu Leu Arg Asp Leu Val Arg Glu Ala Glu Lys Val 405 410 415 Tyr Tyr Arg Arg Glu Thr Glu Glu Glu Lys Glu Gln Arg Lys Glu Lys 420 425 430 Glu Arg Glu Glu Arg Glu Glu Arg Arg Arg Arg Gln Glu Lys Asn 435 440 445 Leu Thr Lys Ile Leu Ala Ala Val Val Glu Gly Lys Ser Ser Arg Glu 450 460 Arg Glu Arg Asp Phe Arg Lys Ile Arg Ser Gly Pro Arg Gln Ser Gly 465 475 480 Asn Leu Gly Asn Arg Thr Pro Leu Asp Lys Asp Gln Cys Ala Tyr Cys 485 490 495 Lys Glu Lys Gly His Trp Ala Arg Asn Cys Pro Lys Lys Gly Asn Lys $500 \hspace{1.5cm} 510 \hspace{1.5cm}$ Gly Pro Lys Val Leu Ala Leu Glu Glu Asp Lys Asp <210> 2

<211> 660

<212> PRT

<213> porcine endogenous retrovirus Type PERV A

<400>

Met His Pro Thr Leu Ser Arg Arg His Leu Pro Ile Arg Gly Gly Lys
Pro Lys Arg Leu Lys Ile Pro Leu Ser Phe Ala Ser Ile Ala Trp Phe
Leu Thr Leu Ser Ile Thr Pro Gln Val Asn Gly Lys Arg Leu Val Asp

Ser Pro Asn Ser His Lys Pro Leu Ser Leu Thr Trp Leu Leu Thr Asp 50 60 Ser Gly Thr Gly Ile Asn Ile Asn Ser Thr Gln Gly Glu Ala Pro Leu 65 70 75 80 Gly Thr Trp Trp Pro Glu Leu Tyr Val Cys Leu Arg Ser Val Ile Pro Gly Leu Asn Asp Gln Ala Thr Pro Pro Asp Val Leu Arg Ala Tyr Gly $100 \hspace{0.5cm} 105 \hspace{0.5cm} 110$ Phe Tyr Val Cys Pro Gly Pro Pro Asn Asn Glu Glu Tyr Cys Gly Asn 115 120 125 Pro Gln Asp Phe Phe Cys Lys Gln Trp Ser Cys Ile Thr Ser Asn Asp 130 135 140 Gly Asn Trp Lys Trp Pro Val Ser Gln Gln Asp Arg Val Ser Tyr Ser 145 150 155 160 Phe Val Asn Asn Pro Thr Ser Tyr Asn Gln Phe Asn Tyr Gly His Gly 165 170 175 Arg Trp Lys Asp Trp Gln Gln Arg Val Gln Lys Asp Val Arg Asn Lys $180 \ \ \, 185 \ \ \, 190 \ \ \,$ Gln Ile Ser Cys His Ser Leu Asp Leu Asp Tyr Leu Lys Ile Ser Phe Thr Glu Lys Gly Lys Gln Glu Asn Ile Gln Lys Trp Val Asn Gly Ile 210 215 220 Ser Trp Gly Ile Val Tyr Tyr Gly Gly Ser Gly Arg Lys Lys Gly Ser 225 230 235 Val Leu Thr Ile Arg Leu Arg Ile Glu Thr Gln Met Glu Pro Pro Val Ala Ile Gly Pro Asn Lys Gly Leu Ala Glu Gln Gly Pro Pro Ile Gln 260 260 Glu Gln Arg Pro Ser Pro Asn Pro Ser Asp Tyr Asn Thr Thr Ser Gly 275 280 285 Ser Val Pro Thr Glu Pro Asn Ile Thr Ile Lys Thr Gly Ala Lys Leu $290\,$ Phe Ser Leu Ile Gln Gly Ala Phe Gln Ala Leu Asn Ser Thr Thr Pro 305 310 315Glu Ala Thr Ser Ser Cys Trp Leu Cys Leu Ala Ser Gly Pro Pro Tyr $\frac{325}{330}$ Tyr Glu Gly Met Ala Arg Gly Gly Lys Phe Asn Val Thr Lys Glu His 340 345 Arg Asp Gln Cys Thr Trp Gly Ser Gln Asn Lys Leu Thr Leu Thr Glu 355 360 365 val Ser Gly Lys Gly Thr Cys Ile Gly Met Val Pro Pro Ser His Gln $_{370}^{\rm Val}$ His Leu Cys Asn His Thr Glu Ala Phe Asn Arg Thr Ser Glu Ser Gln 385 390 395 Tyr Leu Val Pro Gly Tyr Asp Arg Trp Trp Ala Cys Asn Thr Gly Leu 405 410 415 Thr Pro Cys Val Ser Thr Leu Val Phe Asn Gln Thr Lys Asp Phe Cys 420 - 425 430 Val Met Val Gln Ile Val Pro Arg Val Tyr Tyr Pro Glu Lys Ala 435 440 445 Val Leu Asp Glu Tyr Asp Tyr Arg Tyr Asn Arg Pro Lys Arg Glu Pro Ile Ser Leu Thr Leu Ala Val Met Leu Gly Leu Gly Val Ala Ala Gly 465 470 475 Val Gly Thr Gly Thr Ala Ala Leu Ile Thr Gly Pro Gln Gln Leu Glu 485 490 495 Lys Gly Leu Ser Asn Leu His Arg Ile Val Thr Glu Asp Leu Gln Ala Leu Glu Lys Ser Val Ser Asn Leu Glu Glu Ser Leu Thr Ser Leu Ser 515 Glu Val Val Leu Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Leu Lys 530 540 Glu Gly Gly Leu Cys val Ala Leu Lys Glu Glu Cys Cys Phe Tyr Val 545 550 560 Asp His Ser Gly Ala Ile Arg Asp Ser Met Ser Lys Leu Arg Glu Arg 565 570 575 Leu Glu Arg Arg Arg Glu Arg Glu Ala Asp Gln Gly Trp Phe Glu 580 585 590 Gly Trp Phe Asn Arg Ser Pro Trp Met Thr Thr Leu Leu Ser Ala Leu 595 600 605 Thr Gly Pro Leu Val Val Leu Leu Leu Leu Leu Eu Thr Val Gly Pro Cys 615

Leu Ile Asn Arg Phe Val Ala Phe Val Arg Glu Arg Val Ser Ala Val 625 630 640

Gln Ile Met Val Leu Arg Gln Gln Tyr Gln Gly Leu Leu Ser Gln Gly $645 \hspace{0.5cm} 650 \hspace{0.5cm} 655$

Glu Thr Asp Leu

<210> 3

<400>

<211> 638

<212> PRT

<213> porcine endogenous retrovirus Type PERV MSL

 Met
 His
 Pro
 Thr
 Leu
 Arg
 Arg
 His
 Leu
 Pro
 Ile
 Arg
 Arg
 His
 Leu
 Pro
 Ile
 Arg
 His
 Leu
 Pro
 Ile
 Arg
 His
 Ile
 Pro
 Leu
 Ser
 Phe
 Ala
 Ser
 Ile
 Ala
 Trp
 Phe
 Ala
 Ser
 Ile
 Ala
 Ser
 Ile
 Ala
 Ser
 Ile
 Ala
 Ile
 Ala
 Ile
 Ala
 Ile
 Ala
 Ile
 Ala
 Ile
 Ile
 Ala
 Ile
 Ile
 Ile
 Ala
 Ile
 Ile
 Ile
 Ile
 Ala
 Ile
 Ile
 Ile
 Ile
 Ile
 Ala
 Ile
 Ile</th

Thr Tyr Thr Ser Ser Gly Gln Phe Asn Tyr Leu Thr Trp Ile Arg Thr $165 \ \ \, 170 \ \ \, 175$

Gly Ser Pro Lys Cys Ser Pro Ser Asp Leu Asp Tyr Leu Lys Ile Ser Phe Thr Glu Lys Gly Lys Gln Glu Asn Ile Leu Lys Trp Val Asn Gly Met Ser Trp Gly Met val Tyr Tyr Gly Gly Ser Gly Lys Gln Pro Gly 210 220 Ser Ile Leu Thr Ile Arg Leu Lys Ile Asn Gln Leu Glu Pro Pro Met 225 230 235 240 Ala Ile Gly Pro Asn Thr Val Leu Thr Gly Gln Arg Pro Pro Thr Gln 245 250 255 Gly Pro Gly Pro Ser Ser Asn Ile Thr Ser Gly Ser Asp Pro Thr Glu 260 265 270 Ser Asn Ser Thr Thr Lys Met Gly Ala Lys Leu Phe Ser Leu Ile Gln 275 280 285 Gly Ala Phe Gln Ala Leu Asn Ser Thr Thr Pro Glu Ala Thr Ser Ser 290 295 300 Cys Trp Leu Cys Leu Ala Ser Gly Pro Pro Tyr Tyr Glu Gly Met Ala 305 310315 Arg Arg Gly Lys Phe Asn Val Thr Lys Glu His Arg Asp Gln Cys Thr Trp Gly Ser Gln Asn Lys Leu Thr Leu Thr Glu Val Ser Gly Lys Gly 340 345 350 Thr Cys Ile Gly Lys Val Pro Pro Ser His Gln His Leu Cys Asn His Thr Glu Ala Phe Asn Gln Thr Ser Glu Ser Gln Tyr Leu Val Pro Gly 370 380 Tyr Asp Arg Trp Trp Ala Cys Asn Thr Gly Leu Thr Pro Cys Val Ser 385 390 395 400 Thr Leu Val Phe Asn Gln Thr Lys Asp Phe Cys Ile Met Val Gln Ile 405Val Pro Arg Val Tyr Tyr Tyr Pro Glu Lys Ala Ile Leu Asp Glu Tyr 420 425 430 Asp Tyr Arg Asn His Arg Gln Lys Arg Glu Pro Ile Ser Leu Thr Leu Ala Val Met Leu Gly Leu Gly Val Ala Ala Gly Val Gly Thr Gly Thr Ala Ala Leu Val Thr Gly Pro Gln Gln Leu Glu Thr Gly Leu Ser Asn 465 470 480 Leu His Arg Ile Val Thr Glu Asp Leu Gln Ala Leu Glu Lys Ser Val 485 490 495 Ser Asn Leu Glu Glu Ser Leu Thr Ser Leu Ser Glu Val Val Leu Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Leu Lys Glu Gly Gly Leu Cys 515 520 525 Val Ala Leu Lys Glu Glu Cys Cys Phe Tyr Val Asp His Ser Gly Ala 530 540 Ile Arg Asp Ser Met Asn Lys Leu Arg Glu Arg Leu Glu Lys Arg Arg 545 550 555 560 Arg Glu Lys Glu Thr Thr Gln Gly Trp Phe Glu Gly Trp Phe Asn Arg 565 570 575 Ser Leu Trp Leu Ala Thr Leu Leu Ser Ala Leu Thr Gly Pro Leu Ile $580 \hspace{1.5cm} 590$ Val Leu Leu Leu Leu Thr Val Gly Pro Cys Ile Ile Asn Lys Leu
595 600 605 Ile Ala Phe Ile Arg Glu Arg Ile Ser Ala Val Gln Ile Met Val Leu 610 620 Arg Gln Gln Tyr Gln Ser Pro Ser Ser Arg Glu Ala Gly Arg <210> <211> 638 <212> PRT

<213> porcine endogenous retrovirus Type Tsukuba

<400> 4

Met His Pro Thr Leu Ser Arg Arg His Leu Pro Ile Arg Gly Gly Lys
1

Pro Lys Arg Leu Lys Ile Pro Leu Ser Phe Ala Ser Ile Ala Trp Phe

Leu Thr Leu Ser Ile Thr Ser Gln Thr Asn Gly Met Arg Ile Gly Asp $\frac{400}{15}$

Ser Leu Asn Ser His Lys Pro Leu Ser Leu Thr Trp Leu Ile Thr Asp 50 60Ser Gly Thr Gly Ile Asn Ile Asn Asn Thr Gln Gly Glu Ala Pro Leu Gly Thr Trp Trp Pro Asp Leu Tyr Val Cys Leu Arg Ser Val Ile Pro 85Ser Leu Thr Ser Pro Pro Asp Ile Leu His Ala His Gly Phe Tyr Val 100 105 110 Cys Pro Gly Pro Pro Asn Asn Gly Lys His Cys Gly Asn Pro Arg Asp 115 120 125 Phe Phe Cys Lys Gln Trp Asn Cys Val Thr Ser Asn Asp Gly Tyr Trp 130 135 140 Lys Trp Pro Thr Ser Gln Gln Asp Arg Val Ser Phe Ser Tyr Val Asn 145 150 155 160 Thr Tyr Thr Ser Ser Gly Gln Phe Asn Tyr Leu Thr Trp Ile Arg Thr Gly Ser Pro Lys Cys Ser Pro Ser Asp Leu Asp Tyr Leu Lys Ile Ser 180 185 190Phe Thr Glu Lys Gly Lys Gln Glu Asn Ile Leu Lys Trp Val Asn Gly 195 200 Met Ser Trp Gly Met Val Tyr Tyr Gly Gly Ser Gly Lys Gln Pro Gly 210 225 220 Ser Ile Leu Thr Ile Arg Leu Lys Ile Asn Gln Leu Glu Pro Pro Met 225 230 235 240 Ala Ile Gly Pro Asn Thr Val Leu Thr Gly Gln Arg Pro Pro Thr Gln 245 250 255 Gly Pro Gly Pro Ser Ser Asn Ile Thr Ser Gly Ser Asp Pro Thr Glu 260 265 270Ser Ser Ser Thr Thr Lys Met Gly Ala Lys Leu Phe Ser Leu Ile Gln 275 280 285 Cys Trp Leu Cys Leu Ala Leu Gly Pro Pro Tyr Tyr Glu Gly Met Ala 305 310 315 320 Arg Arg Gly Lys Phe Asn Val Thr Lys Glu His Arg Asp Gln Cys Thr Trp Gly Ser Gln Asn Lys Leu Thr Leu Thr Glu Val Ser Gly Lys Gly 340 345 350Thr Cys Ile Gly Lys Val Pro Pro Ser His Gln His Leu Cys Asn His 355 360 365 Thr Glu Ala Phe Asn Gln Thr Ser Glu Ser Gln Tyr Leu Val Pro Gly 370 375 380 Tyr Asp Arg Trp Trp Ala Cys Asn Thr Gly Leu Thr Pro Cys Val Ser 385 390 395 400 Thr Leu Val Phe Asn Gln Thr Lys Asp Phe Cys Ile Met Val Gln Ile 405 410 415 Val Pro Arg Val Tyr Tyr Pro Glu Lys Ala Ile Leu Asp Glu Tyr 420 425 430 Asp Tyr Arg Asn His Arg Gln Lys Arg Glu Pro Ile Ser Leu Thr Leu 435 440 445 Ala Val Met Leu Gly Leu Gly Val Ala Ala Gly Val Gly Thr Gly Thr 450 455 460 Ala Ala Leu Val Thr Gly Pro Gln Gln Leu Glu Thr Gly Leu Ser Asn 465 470 475 480 Leu His Arg Ile val Thr Glu Asp Leu Gln Ala Leu Glu Lys Ser val 485 490 495 Ser Asn Leu Glu Glu Ser Leu Thr Ser Leu Ser Glu Val Val Leu Gln 500 510 Asn Arg Arg Gly Leu Asp Leu Leu Phe Leu Lys Glu Gly Gly Leu Cys 515 520 525 Val Ala Leu Lys Glu Glu Cys Cys Phe Tyr Val Asp His Ser Gly Ala 530 535 Ile Arg Asp Ser Met Asn Lys Leu Arg Glu Arg Leu Glu Lys Arg Arg 545 550 555 560 Arg Glu Lys Glu Thr Thr Gln Gly Trp Phe Glu Gly Trp Phe Asn Arg 565 570 Ser Pro Trp Leu Ala Thr Leu Leu Ser Ala Leu Thr Gly Pro Leu Ile 580 585 590 Val Leu Leu Leu Leu Thr Val Gly Pro Cys Ile Ile Asn Lys Leu
595 600 605 Ile Ala Phe Ile Arg Glu Arg Ile Ser Ala Val Gln Ile Met Val Leu 610 620

Arg Gln Gln Tyr Gln Ser Pro Ser Ser Arg Glu Ala Gly Arg 625 635

<210> 5

<211> 657

<212> PRT

<213> porcine endogenous retrovirus Type PERV B

<400> 5

Met His Pro Thr Leu Ser Trp Arg His Leu Pro Thr Arg Gly Glu 1 5 10 15 Pro Lys Arg Leu Arg Ile Pro Leu Ser Phe Ala Ser Ile Ala Trp Phe Leu Thr Leu Thr Ile Thr Pro Gln Ala Ser Ser Lys Arg Leu Ile Asp Ser Ser Asn Pro His Arg Pro Leu Ser Leu Thr Trp Leu Ile Ile Asp 50 60 Pro Asp Thr Gly Val Thr Val Asn Ser Thr Arg Gly Val Ala Pro Arg 65 70 75 80 Gly Thr Trp Trp Pro Glu Leu His Phe Cys Leu Arg Leu Ile Asn Pro Ala val Lys Ser Thr Pro Pro Asn Leu Val Arg Ser Tyr Gly Phe Tyr Cys Cys Pro Gly Thr Glu Lys Glu Lys Tyr Cys Gly Gly Ser Gly Glu 115 120 125 Ser Phe Cys Arg Arg Trp Ser Cys Val Thr Ser Asn Asp Gly Asp Trp Lys Trp Pro Ile Ser Leu Gln Asp Arg Val Lys Phe Ser Phe Val Asn 145 150 155 160 Ser Gly Pro Gly Lys Tyr Lys Val Met Lys Leu Tyr Lys Asp Lys Ser

Cys Ser Pro Ser Asp Leu Asp Tyr Leu Lys Ile Ser Phe Thr Glu Lys $180 \hspace{1cm} 185 \hspace{1cm} 190 \hspace{1cm}$

Gly Lys Gln Glu Asn Ile Gln Lys Trp Ile Asn Gly Met Ser Trp Gly Ile Val Phe Tyr Lys Tyr Gly Gly Gly Ala Gly Ser Thr Leu Thr Ile 210 215 Arg Leu Arg Ile Glu Thr Gly Thr Glu Pro Pro Val Ala Val Gly Pro 225 230 235 240 ASP Lys Val Leu Ala Glu Gln Gly Pro Pro Ala Leu Glu Pro Pro His 245 250 255 Asn Leu Pro Val Pro Gln Leu Thr Ser Leu Arg Pro Asp Ile Thr Gln 260 270 Pro Pro Ser Asn Gly Thr Thr Gly Leu Ile Pro Thr Asn Thr Pro Arg 275 280 285 Asn Ser Pro Gly Val Pro Val Lys Thr Gly Gln Arg Leu Phe Ser Leu 290 295 300 lle Gln Gly Ala Phe Gln Ala Ile Asn Ser Thr Asp Pro Asp Ala Thr 305 310 315 Ser Ser Cys Trp Leu Cys Leu Ser Ser Gly Pro Pro Tyr Tyr Glu Gly 325 330 335 Met Ala Lys Glu Gly Lys Phe Asn Val Thr Lys Glu His Arg Asn Gln 340 345 350 Cys Thr Trp Gly Ser Arg Asn Lys Leu Thr Leu Thr Glu Val Ser Gly 355Lys Gly Thr Cys Ile Gly Lys Ala Pro Pro Ser His Gln His Leu Cys 370 375 380 Tyr Ser Thr val val Tyr Glu Gln Ala Ser Glu Asn Gln Tyr Leu val 385 390 395 400 Pro Gly Tyr Asn Arg Trp Trp Ala Cys Asn Thr Gly Leu Thr Pro Cys val Ser Thr Ser Val Phe Asn Gln Ser Lys Asp Phe Cys Val Met Val 420 425 430 Gln Ile Val Pro Arg Val Tyr Tyr His Pro Glu Glu Val Val Leu Asp 435 440 445 Thr Leu Ala val Met Leu Gly Leu Gly Thr Ala val Gly val Gly Thr 465 470 475 Gly Thr Ala Ala Leu Ile Thr Gly Pro Gln Gln Leu Glu Lys Gly Leu
485 490 495 Gly Glu Leu His Ala Ala Met Thr Glu Asp Leu Arg Ala Leu Glu Glu 500 510 Ser Val Ser Asn Leu Glu Glu Ser Leu Thr Ser Leu Ser Glu Val Val 515 520 525 Leu Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Leu Arg Glu Gly Gly 530 540 Leu Cys Ala Ala Leu Lys Glu Glu Cys Cys Phe Tyr Val Asp His Ser 545 550 555 560 Gly Ala Ile Arg Asp Ser Met Ser Lys Leu Arg Glu Arg Leu Glu Arg 565 570 575 Arg Arg Arg Glu Arg Glu Ala Asp Gln Gly Trp Phe Glu Gly Trp Phe 580 590Asn Arg Ser Pro Trp Met Thr Thr Leu Leu Ser Ala Leu Thr Gly Pro Leu Val Val Leu Leu Leu Leu Leu Thr Val Gly Pro Cys Leu Ile Asn 610 620 Arg Phe Val Ala Phe Val Arg Glu Arg Val Ser Ala Val Gln Ile Met Val Leu Arg Gln Gln Tyr Gln Gly Leu Leu Ser Gln Gly Glu Thr Asp
645 650 655 Leu

<210>

<211> 656

<212> PRT

<213> porcine endogenous retrovirus Type PoEV1

<400> 6

Met His Pro Thr Leu Ser Arg Arg His Leu Pro Thr Arg Gly Gly Glu

Pro Lys Arg Leu Arg Ile Pro Leu Ser Phe Ala Ser Ile Ala Trp Phe 20 25 30

Leu Thr Leu Thr Ile Thr Pro Gln Ala Ser Ser Lys Arg Leu Ile Asp Pro Asp Thr Gly Val Thr Val Asn Ser Thr Arg Gly Val Ala Pro Arg 65 70 75 80 Gly Thr Trp Trp Pro Glu Leu His Phe Cys Leu Arg Leu Ile Asn Pro Ala Val Lys Ser Thr Pro Pro Asn Leu Val Arg Ser Tyr Gly Phe Tyr Cys Cys Pro Gly Thr Glu Lys Glu Lys Tyr Cys Gly Gly Ser Gly Glu 115 120 125 Ser Phe Cys Arg Arg Trp Ser Cys Val Thr Ser Asn Asp Gly Asp Trp Lys Trp Pro Ile Ser Leu Gln Asp Arg Val Lys Phe Ser Phe Val Asn 145 150 155 160 Ser Gly Pro Gly Lys Tyr Lys Met Met Lys Leu Tyr Lys Asp Lys Ser Cys Ser Pro Ser Asp Leu Asp Tyr Leu Lys Ile Ser Phe Thr Glu Arg 180 Lys Thr Gly Lys Tyr Ser Lys Val Asp Lys Trp Tyr Glu Leu Gly Asn 195 200 205 Ser Phe Leu Leu Tyr Gly Gly Gly Ala Gly Ser Thr Leu Thr Ile Arg 210 215 220 Leu Arg Ile Glu Thr Gly Thr Glu Pro Pro Val Ala Met Gly Pro Asp 225 230 235 240 Lys Val Leu Ala Glu Gln Gly Pro Pro Ala Leu Glu Pro Pro His Asn 245 250 255 Leu Pro Val Pro Gln Leu Thr Ser Leu Arg Pro Asp Ile Thr Gln Pro 260 265 270 Pro Ser Asn Ser Thr Thr Gly Leu Ile Pro Thr Asn Thr Pro Arg Asn 275 280 285 Ser Pro Gly Val Pro Val Lys Thr Gly Gln Arg Leu Phe Ser Leu Ile 290 295 300 Ser Cys Trp Leu Cys Leu Ser Ser Gly Pro Pro Tyr Tyr Glu Gly Met $\frac{325}{330}$ Thr Trp Gly Ser Arg Asn Lys Leu Thr Leu Thr Glu Val Ser Gly Lys 355 360 365 Gly Thr Cys Ile Gly Lys Ala Pro Pro Ser His Gln His Leu Cys Tyr 370 380 Ser Thr Val Val Tyr Glu Gln Ala Ser Glu Asn Gln Tyr Leu Val Pro 385 390 395 400 Gly Tyr Asn Arg Trp Trp Ala Cys Asn Thr Gly Leu Thr Pro Cys Val 405 410 415 Ser Thr Ser Val Phe Asn Gln Ser Lys Asp Phe Cys Val Met Val Gln 420 425 Ile Val Pro Arg Val Tyr Tyr His Pro Glu Glu Val Val Leu Asp Glu 435 440 445 Tyr Asp Tyr Arg Tyr Asn Arg Pro Lys Arg Glu Pro Val Ser Leu Thr 450 455 460 Leu Ala Val Met Leu Gly Leu Gly Thr Ala Val Gly Val Gly Thr Gly 465 470 475 Thr Ala Ala Leu Ile Thr Gly Pro Gln Gln Leu Glu Lys Gly Leu Gly
490
495 Glu Leu His Ala Ala Met Thr Glu Asp Leu Arg Ala Leu Lys Glu Ser 500 510 Val Ser Asn Leu Glu Glu Ser Leu Thr Ser Leu Ser Glu Val Val Leu 515 520 525 Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Leu Arg Glu Gly Gly Leu 530 540 Cys Ala Ala Leu Lys Glu Glu Cys Cys Phe Tyr Val Asp His Ser Gly 545 550 560 Ala Ile Arg Asp Ser Met Asn Lys Leu Arg Lys Lys Leu Glu Arg Arg 565 570 575 Arg Arg Glu Arg Glu Ala Asp Gln Gly Trp Phe Glu Gly Trp Phe Asn

<210> 7

<211> 221

<212> PRT

<213> porcine endogenous retrovirus Type PERV A

<400> 7 Trp Ser Cys Ile Thr Ser Asn Asp Gly Asn Trp Lys Trp Pro Val Ser 20 25 30 Gln Gln Asp Arg Val Ser Tyr Ser Phe Val Asn Asn Pro Thr Ser Tyr 35 40 45 Asn Gln Phe Asn Tyr Gly His Gly Arg Trp Lys Asp Trp Gln Gln Arg 50 60val Gln Lys Asp val Arg Asn Lys Gln Ile Ser Cys His Ser Leu Asp 65 70 75 80 Leu Asp Tyr Leu Lys Ile Ser Phe Thr Glu Lys Gly Lys Gln Glu Asn Ile Gln Lys Trp val Asn Gly Ile Ser Trp Gly Ile val Tyr Tyr Gly $100 \qquad 105 \qquad 110$ Gly Ser Gly Arg Lys Lys Gly Ser Val Leu Thr Ile Arg Leu Arg Ile 115 120 125 Glu Thr Gln Met Glu Pro Pro Val Ala Ile Gly Pro Asn Lys Gly Leu 130 135 140 Ala Glu Gln Gly Pro Pro Ile Gln Glu Gln Arg Pro Ser Pro Asn Pro 145 150 155 160 Ser Asp Tyr Asn Thr Thr Ser Gly Ser Val Pro Thr Glu Pro Asn Ile $165 \\ 165 \\ 170 \\ 175$

Thr Ile Lys Thr Gly Ala Lys Leu Phe Ser Leu Ile Gln Gly Ala Phe 180 190

Gln Ala Leu Asn Ser Thr Thr Pro Glu Ala Thr Ser Ser Cys Trp Leu 195 $200\,$ 205

Cys Leu Ala Ser Gly Pro Pro Tyr Tyr Glu Gly Met Ala 210 215 220

<210> 8

<211> 203

<212> PRT

<213> porcine endogenous retrovirus Type PERV MSL

<400> 8

Ash Ash Gly Lys His Cys Gly Ash Pro Arg Asp Phe Phe Cys Lys Gln

Trp Ash Cys Val Thr Ser Ash Asp Gly Tyr Trp Lys Trp Pro Thr Ser

Gln Gln Asp Arg Val Ser Phe Ser Tyr Val Ash Thr Tyr Thr Ser Ser

Gly Gln Phe Ash Tyr Leu Thr Trp Ile Arg Thr Gly Ser Pro Lys Cys

Ser Pro Ser Asp Leu Asp Tyr Leu Lys Ile Ser Phe Thr Glu Lys Gly

Kys Gln Glu Ash Ile Leu Lys Trp Val Ash Gly Met Ser Trp Gly Met

Val Tyr Tyr Gly Gly Ser Gly Lys Gln Pro Gly Ser Ile Leu Thr Ile

Arg Leu Lys Ile Ash Gln Leu Glu Pro Pro Met Ala Ile Gly Pro Ash

Thr Val Leu Thr Gly Gln Arg Pro Pro Thr Gln Gly Pro Gly Pro Ser

Ser Ash Ile Thr Ser Gly Ser Asp Pro Thr Glu Ser Ash Ser Thr Thr

Lys Met Gly Ala Lys Leu Phe Ser Leu Ile Gln Gly Ala Phe Gln Ala

Leu Asn Ser Thr Thr Pro Glu Ala Thr Ser Ser Cys Trp Leu Cys Leu 185 190

Ala Ser Gly Pro Pro Tyr Tyr Glu Gly Met Ala 195 200

<210> 9

<211> 203

<212> PRT

<213> porcine endogenous retróvirus Type Tsukuba

<400> 9

Asn Asn Gly Lys His Cys Gly Asn Pro Arg Asp Phe Phe Cys Lys Gln $1 \ \ \, 10 \ \ \, 15$

Trp Asn Cys Val Thr Ser Asn Asp Gly Tyr Trp Lys Trp Pro Thr Ser 20 25 30

Gln Gln Asp Arg Val Ser Phe Ser Tyr Val Asn Thr Tyr Thr Ser Ser 35 40 45

Gly Gln Phe Asn Tyr Leu Thr Trp Ile Arg Thr Gly Ser Pro Lys Cys $50 \hspace{1cm} \text{Gly Ser}$

Ser Pro Ser Asp Leu Asp Tyr Leu Lys Ile Ser Phe Thr Glu Lys Gly $65 \ \ \, 70 \ \ \, 75$

Lys Gln Glu Asn Ile Leu Lys Trp Val Asn Gly Met Ser Trp Gly Met $85 \\ 00$

val Tyr Tyr Gly Gly Ser Gly Lys Gln Pro Gly Ser Ile Leu Thr Ile $100 \ \ 105 \ \ \ \ 110$

Arg Leu Lys Ile Asn Gln Leu Glu Pro Pro Met Ala Ile Gly Pro Asn 115 120 125

Thr Val Leu Thr Gly Gln Arg Pro Pro Thr Gln Gly Pro Gly Pro Ser $130 \,$ $135 \,$ $140 \,$

Ser Asn Ile Thr Ser Gly Ser Asp Pro Thr Glu Ser Ser Ser Thr Thr 145 150 155 160

Lys Met Gly Ala Lys Leu Phe Ser Leu Ile Gln Gly Ala Phe Gln Ala 165 170 175

Leu Asn Ser Thr Thr Pro Glu Ala Thr Ser Ser Cys Trp Leu Cys Leu 180 185 190

Ala Leu Gly Pro Pro Tyr Tyr Glu Gly Met Ala 195 200 <210> 10

<211> 221

<212> PRT

<213> porcine endogenous retrovirus Type PERV B

<400> 10

Glu Lys Glu Lys Tyr Cys Gly Gly Ser Gly Glu Ser Phe Cys Arg Arg Trp Ser Cys Val Thr Ser Asn Asp Gly Asp Trp Lys Trp Pro Ile Ser Leu Gln Asp Arg Val Lys Phe Ser Phe Val Asn Ser Gly Pro Gly Lys Tyr Lys Val Met Lys Leu Tyr Lys Asp Lys Ser Cys Ser Pro Ser Asp Leu Asp Tyr Leu Lys Ile Ser Phe Thr Glu Lys Gly Lys Gln Glu Asn Ile Gln Lys Trp Ile Asn Gly Met Ser Trp Gly Ile Val Phe Tyr Lys Tyr Gly Gly Gly Ala Gly Ser Thr Leu Thr Ile Arg Leu Arg Ile Glu Thr Gly Thr Glu Pro Pro Val Ala Val Gly Pro Asp Lys Val Leu Ala Glu Gln Gly Pro Pro Ala Leu Glu Pro Pro His Asn Leu Pro Val Pro Gln Leu Thr Ser Leu Arg Pro Asp Ile Thr Gln Pro Pro Ser Asn Gly 145 150 155 160 Thr Thr Gly Leu Ile Pro Thr Asn Thr Pro Arg Asn Ser Pro Gly Val Pro Val Lys Thr Gly Gln Arg Leu Phe Ser Leu Ile Gln Gly Ala Phe 180 185 190 Gln Ala Ile Asn Ser Thr Asp Pro Asp Ala Thr Ser Ser Cys Trp Leu 195 200 205 Cys Leu Ser Ser Gly Pro Pro Tyr Tyr Glu Gly Met Ala 210 215 220

<210> 11

<211> 220

<212> PRT

<213> porcine endogenous retrovirus Type POEV1

<400> 11

Glu Lys Glu Lys Tyr Cys Gly Gly Ser Gly Glu Ser Phe Cys Arg Arg 10 15

Trp Ser Cys Val Thr Ser Asn Asp Gly Asp Trp Lys Trp Pro Ile Ser 20 25 30

Leu Gln Asp Arg Val Lys Phe Ser Phe Val Asn Ser Gly Pro Gly Lys

Tyr Lys Met Met Lys Leu Tyr Lys Asp Lys Ser Cys Ser Pro Ser Asp 50 60

Leu Asp Tyr Leu Lys Ile Ser Phe Thr Glu Arg Lys Thr Gly Lys Tyr

Ser Lys Val Asp Lys Trp Tyr Glu Leu Gly Asn Ser Phe Leu Leu Tyr

Gly Gly Gly Ala Gly Ser Thr Leu Thr Ile Arg Leu Arg Ile Glu Thr $100 ext{ } 105 ext{ } 110$

Gly Thr Glu Pro Pro Val Ala Met Gly Pro Asp Lys Val Leu Ala Glu 115 120 125

Gln Gly Pro Pro Ala Leu Glu Pro Pro His Asn Leu Pro Val Pro Gln 130 135 140

Leu Thr Ser Leu Arg Pro Asp Ile Thr Gln Pro Pro Ser Asn Ser Thr 145 150

Thr Gly Leu Ile Pro Thr Asn Thr Pro Arg Asn Ser Pro Gly Val Pro 165 170 175

Val Lys Thr Gly Gln Arg Leu Phe Ser Leu Ile Gln Gly Ala Phe Gln 180 185 190

Ala Ile Asn Ser Thr Asp Pro Asp Ala Thr Ser Ser Cys Trp Leu Cys $195 \hspace{0.5cm} 200 \hspace{0.5cm} 205 \hspace{0.5cm}$

Leu Ser Ser Gly Pro Pro Tyr Tyr Glu Gly Met Ala 210 215 220

```
<211> 15
<212> PRT
<213> porcine endogenous retrovirus
<400> 12
Arg Glu Glu Arg Arg Asp Arg Arg Gln Glu Lys Asn Leu Thr Lys 10 \ 10 \ 15
<210> 13
<211> 14
<212> PRT
<213> porcine endogenous retrovirus
<400> 13
Ala arg Asn Cys Pro Lys Lys Gly Asn Lys Gly Pro Lys Val 1 	 10
<210> 14
<211> 16
<212> PRT
<213> porcine endogenous retrovirus Type PoEV1
<400> 14
Thr Ser Leu Arg Pro Asp Ile Thr Gln Pro Pro Ser Asn Ser Thr Thr 1 10 15
<210> 15
<211> 15
<212> PRT
<213> porcine endogenous retrovirus Type PERV B
<210> 16
 <211> 18
 <212> PRT
 <213> porcine endogenous retrovirus Type PoEV1
```

```
<400> 16
Arg Lys Thr Gly Lys Tyr Ser Lys Val Asp Lys Trp Tyr Glu Leu Gly 1 \hspace{1.5cm} 10 \hspace{1.5cm} 15
Asn Ser
<210> 17
<211> 12
<212> PRT
<213> porcine endogenous retrovirus Type Tsukuba
<400> 17
Asn Thr Val Leu Thr Gly Gln Arg Pro Pro Thr Gln
1 10
<210> 18
<211> 22
<212> PRT
<213> porcine endogenous retrovirus Type PERV A
<400> 18
Gly His Gly Arg Trp Lys Asp Trp Gln Gln Arg Val Gln Lys Asp Val 1000 15
Arg Asn Lys Gln Ile Ser
 <210> 19
 <211> 16
 <212> PRT
 <213> porcine endogenous retrovirus Type PERV A
 <400> 19
 Ile Gln Glu Gln Arg Pro Ser Pro Asn Pro Ser Asp Tyr Asn Thr Thr 1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15
```